23-11-2018

10:00 - 11:30  Type: Opening session  
Title: Opening & Keynote  
Chair: Josep Tabernero, ES

10:00 - 10:10  Opening

10:10 - 10:15  Welcome address by the ESMO President  
J. Tabernero, ES

10:15 - 10:25  Welcome address by the Senior Minister of State in the Ministry of Health and the Ministry of Transport  
L. P. Min, SG

10:25 - 10:30  Welcome address by the President of the Singapore Society of Oncology  
S. P. Choo, SG

10:30 - 10:50  Presentation of Token of Appreciation to the Endorsing National Oncology Societies  
J. Tabernero, ES

10:50 - 11:00  Scientific address  
T. S. K. Mok\textsuperscript{1}, S. Banerjee\textsuperscript{2}; 1HK, 2GB

11:00 - 11:30  ESMO Presidential Address  
J. Tabernero, ES

11:45 - 12:30  Type: Challenge Your Expert session  
Title: Treatment of node positive bladder  
Chair: Ji Youl Lee, KR; Ben Tran, AU

11:45 - 12:05  Treatment of node positive bladder  
J. Y. Lee\textsuperscript{1}, B. Tran\textsuperscript{2}; 1KR, 2AU

12:05 - 12:30  Discussion led by  
J. Y. Lee\textsuperscript{1}, B. Tran\textsuperscript{2}; 1KR, 2AU
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Hall</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 - 12:30</td>
<td>Challenge Your Expert session</td>
<td>Treatment for stage IIb cervical cancer: Surgery or chemoradiation?</td>
<td>404</td>
<td>Andres Maria Poveda Velasco, ES</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td></td>
<td>Treatment for stage IIb cervical cancer: Surgery or chemoradiation?</td>
<td></td>
<td>J-W. Kim, KR</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td>Discussion led by</td>
<td></td>
<td>A.M. Poveda Velasco, ES</td>
</tr>
<tr>
<td>11:45 - 12:30</td>
<td>Challenge Your Expert session</td>
<td>Management of early breast cancer in young women</td>
<td>407</td>
<td>Binghe Xu, CN</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td></td>
<td>Management of early breast cancer in young women</td>
<td></td>
<td>L. Del Mastro, IT</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td>Discussion led by</td>
<td></td>
<td>B. Xu, CN</td>
</tr>
<tr>
<td>11:45 - 12:30</td>
<td>Challenge Your Expert session</td>
<td>Skull base tumours</td>
<td>324</td>
<td>Lisa Licitra, IT</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td></td>
<td>Skull base tumours</td>
<td></td>
<td>P. Pai, IN</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td>Discussion led by</td>
<td></td>
<td>L. Licitra, IT</td>
</tr>
<tr>
<td>11:45 - 12:30</td>
<td>Challenge Your Expert session</td>
<td>What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma?</td>
<td>311</td>
<td>Herbert Loong, HK</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td></td>
<td>What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma?</td>
<td></td>
<td>A. Le Cesne, CEDEX/FR</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td>Discussion led by</td>
<td></td>
<td>H. Loong, HK</td>
</tr>
<tr>
<td>12:45 - 14:15</td>
<td>Industry Satellite Symposium</td>
<td>Industry Satellite Symposium</td>
<td>405</td>
<td></td>
</tr>
</tbody>
</table>
12:45 - 14:15  Type: Industry Satellite Symposium
Title: Industry Satellite Symposium
Hall 404

12:45 - 14:15  Type: Industry Satellite Symposium
Title: Industry Satellite Symposium
Hall 407

12:45 - 14:15  Type: Industry Satellite Symposium
Title: Industry Satellite Symposium
Room 324

12:45 - 14:15  Type: ESMO Colloquium
Title: ESMO COLLOQUIUM - Immunotherapy of lung cancer: Alone or in combination?
Room 311

12:45 - 12:50  Introduction
T. Mitsudomi, JP

12:50 - 13:10  1st line immunotherapy options for patients without an oncogene driver
R. Soo, SG

13:10 - 13:30  What is the biological rationale for combining chemotherapy with immune checkpoints inhibitors?
M. Garassino, IT

13:30 - 13:50  Are ICPs better as single agent, doublet ICPs or combined with Chemo +/- anti-angiogenics?
S. Peters, CH

13:50 - 14:10  What’s new in the guidelines for immune therapy of metastatic NSCLC?
D. Planchard, FR

14:10 - 14:15  Conclusions
T. Mitsudomi, JP
### Controversies in lung cancer immuno-oncology

**Chair:** Raffaele Califano, GB; Ross Soo, SG

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:55</td>
<td>Immuno checkpoint blockade for advanced NSCLC: What is the role in the elderly and patients with PS2?</td>
<td>R. Califano, GB</td>
</tr>
<tr>
<td>14:55 - 15:20</td>
<td>Immuno checkpoint blockade for oncogene-addicted NSCLC</td>
<td>R. Soo, SG</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Immunotherapy in GI cancers: Current status & future perspectives

**Chair:** Claus-Henning Koehne, DE; Yung-Jue Bang, KR

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Biomarkers for immunotherapy</td>
<td>B. Ma, HK</td>
</tr>
<tr>
<td>14:45 - 15:05</td>
<td>Immunotherapy in gastric cancer</td>
<td>Y.-J. Bang, KR</td>
</tr>
<tr>
<td>15:05 - 15:25</td>
<td>Immunotherapy in hepatocellular carcinoma (HCC)</td>
<td>T. Okusaka, JP</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
14:30 - 14:42 39O - Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized Phase III MONALEESA-7 study

S.-A. Im1, J. Sohn1, D. Tripathy2, L. Chow3, K.S. Lee1, K.H. Jung1, G. Babu4, Y.-H. Im1, N. El Saghir5, M.-C. Liu6, I. Diaz-Padilla7, J. Alam8, O. Kong8, M. Miller8, Y.-S. Lu6; 1KR, 2TX/US, 3HK, 4IN, 5LB, 6TW, 7CH, 8NJ/US

14:42 - 14:52 Invited discussant

M. Toi, JP

14:52 - 15:04 69O - Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach


15:04 - 15:16 LBA4 - Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001


15:16 - 15:31 Invited discussant

T. Yap, Surrey/US

15:31 - 15:43 252O - MMR deficiency(d) in an unselected cohort of endometrial cancer (EC) patients, the Royal Marsdien experience

C. Orbegoso Aguilar, K. Vroobel, A. Attygalle, S. Lalondrelle, A. Taylor, M. Nobbenhuis, S. Banerjee, A. George; GB

15:43 - 15:53 Invited discussant

C. Scott, AU
14:30 - 16:00  Type: Special Session  
Title: Skin toxicity  
Chair: Carsten Bokemeyer, DE

14:30 - 14:35  Introduction  
C. Bokemeyer, DE

14:35 - 14:55  Hair loss and management  
F. Boyle, AU

14:55 - 15:15  EGFR associated skin toxicities  
C. Bokemeyer, DE

15:15 - 15:35  Immuno-related skin reactions

15:35 - 15:55  Hand-foot syndrome  
Y.S. Yap, SG

15:55 - 16:00  Conclusion

14:30 - 16:00  Type: Special Session  
Title: Controversial cases of melanomas and sarcomas  
Chair: Axel Le Cesne, FR; Akira Kawai, JP; Richard Quek, SG

14:30 - 14:35  Presentation of case/condition  
A. Le Cesne, CEDEX/FR

14:35 - 14:55  A 32-year old woman presenting with a large right thigh mass (high risk synovial sarcoma)  
A. Kawai, JP

14:55 - 15:15  A 32-year old man presenting with gastrointestinal bleeding (intra-abdominal clear cell sarcoma)  
A. Le Cesne, CEDEX/FR

15:15 - 15:35  A 32-years old man with an acral lentiginous melanoma of the big toe with popliteal lymph node involvement  
R. Quek, SG

15:35 - 16:00  General discussion
### Educational session

**Title:** The challenges of cancer care in low and middle-income countries  
Chair: Soe Aung, MM  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:55</td>
<td>Education and training in low and middle-income countries: How can ESMO foster regional collaboration among Asian regional institutions?</td>
<td>K. Sharma, IN</td>
</tr>
<tr>
<td>14:55 - 15:20</td>
<td>How to build capacity to perform clinical trials and cancer research in LMICs</td>
<td>B. Gyawali, Aichi/US</td>
</tr>
<tr>
<td>15:20 - 15:45</td>
<td>Strategies for managing cancer treatment and palliative care with limited resources</td>
<td>G.S. Bhattacharyya, West Bengal/IN</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>General discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Young Oncologist session

**Title:** Meet your mentor  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:30</td>
<td>Presentation of case of recurrent cervical cancer</td>
<td>J.-W. Kim, KR</td>
</tr>
<tr>
<td>16:30 - 18:00</td>
<td>Prognostic and predictive factors including human papillomavirus (HPV)</td>
<td>H.Y.-S. Ngan, HK</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td>Surgical considerations</td>
<td>M.-C. Lim, KR</td>
</tr>
<tr>
<td>17:20 - 17:40</td>
<td>Advances in systemic therapy</td>
<td>A. Oaknin, ES</td>
</tr>
<tr>
<td>17:40 - 18:00</td>
<td>General discussion and conclusions</td>
<td>K. Fujiwara, JP</td>
</tr>
</tbody>
</table>
16:30 - 16:35  
**Introduction**  
J. Tabernero, ES

16:35 - 16:45  
**Existing challenges for uptake of oncology biosimilars in Asia**  
J. Tabernero, ES

16:45 - 17:00  
**ESMO survey on biosimilars in oncology - results**  
M. Vyas, BE

17:00 - 17:15  
**India: Tackling the rising demand for medicines with locally developed biosimilars**  
G.S. Bhattacharyya, West Bengal/IN

17:15 - 17:30  
**One year on - state of play in the APAC region on oncology biosimilars**  
S. Magaz, SG

17:30 - 17:50  
**Panel Discussion with industry representatives**

17:50 - 17:55  
**Conclusions**  
J. Tabernero, ES
16:30 - 16:45  **LBA7 - Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)**

M. Hochmair¹, A. Morabito², D. Hao³, C.-T. Yang⁴, R. Soo⁵, J. Yang⁴, R. Gucalp⁶, B. Halmos⁶, L. Wang⁴, A. Golembesky⁷, A. Märtten⁷, T. Cufer⁸; ¹AT, ²IT, ³AB/CA, ⁴TW, ⁵SG, ⁶AL/US, ⁷DE, ⁸SI

16:45 - 17:00  **LBA8 - Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study**


17:00 - 17:15  **Invited discussant**

S. Ekman, SE

17:15 - 17:30  **LBA9 - IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations**


17:30 - 17:40  **Invited discussant**

S. Lu, CN

17:40 - 17:55  **547O - Stereotactic Ablative Radiotherapy for oligometastatic cancers: Efficacy and Toxicity Results from the randomized SABR-COMET Trial**

S. Senan¹, R. Olson², S. Harrow³, S. Gaede⁴, A. Louie⁴, C. Haasbeek¹, L. Mulroy⁵, M. Lock⁴, G. Rodrigues⁴, B. Yaremko⁴, D. Schellenberg⁵, B. Ahmad⁴, G. Griffioen¹, S. Senthi⁶, M. Liu⁷, K. Moore³, S. Currie³, G. Bauman⁴, A. Warner⁴, D. Palma⁴; ¹NL, ²BC/CA, ³GB, ⁴ON/CA, ⁵AB/CA, ⁶ACT/AU, ⁷CA

17:55 - 18:05  **Invited discussant**

M.L.K. Chua, SG
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:30 - 18:00| **Type:** Educational session  
**Title:** Rational development of immuno-oncology combinations  
Room 324  
Chair: Daniel Shao Weng Tan, SG |
| 16:30 - 16:55| **Non-clinical models (including immunoavatars) for development of immuno-oncology combinations**  
R. Stripecke, DE |
| 16:55 - 17:20| **Lessons learned from immuno-oncology combinations in the clinic**  
T. Yap, Surrey/US |
| 17:20 - 17:45| **Clinical trial designs, biomarkers and endpoints for immuno-oncology combinations**  
S.-B. Kim, KR |
| 17:45 - 18:00| **Cancer evolution and immuno escape**  
N. McGranahan, GB |
| 16:30 - 18:00| **Type:** Multidisciplinary tumour board  
**Title:** Oligometastatic prostate cancer  
Room 311  
Chair: Ravindran Kanesvaran, SG; Shigeo Horie, JP; Ji Youl Lee, KR; Yuji Miura, JP |
| 16:30 - 16:35| **Presentation of case/condition**  
S. Horie, JP |
| 16:35 - 16:55| **Cutting edge science of oligometastatic**  
R. Kanesvaran, SG |
| 16:55 - 17:15| **Role of surgery in oligometastatic prostate cancer**  
J.Y. Lee, KR |
| 17:15 - 17:35| **ADT and chemotherapy in oligometastatic prostate cancer**  
Y. Miura, JP |
| 17:35 - 18:00| **Discussion** |
16:30 - 17:30  Type: Special Session
Title: Caring for AYA with cancer in Europe and Asia: Different challenges, same Goals
Chair: Jean-Yves Douillard, CH; Chi-kong Li, CN

16:30 - 16:35  Introduction
J.Y. Douillard, CH

16:35 - 16:50  The current situation in Europe: Challenges and opportunities
G. Mountzios, GR

16:50 - 17:05  The current situation in Asia: Challenges and opportunities
C.-K. Li, CN

17:05 - 17:25  Results of the Joint ESMO/SIOPE/SIOP Asia survey on AYA with cancer
R. Dalvi, IN

17:25 - 17:30  Conclusions
C.-K. Li, CN
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:25</td>
<td>Landscape of somatic and germline mutation in patients with breast cancer in Asia</td>
</tr>
<tr>
<td></td>
<td>P. Yuan, CN</td>
</tr>
<tr>
<td>09:25 - 09:50</td>
<td>Management of patients with BRCA1 and BRCA2 mutated early breast cancer</td>
</tr>
<tr>
<td></td>
<td>S. Delaloge, FR</td>
</tr>
<tr>
<td>09:50 - 10:15</td>
<td>Targeting BRCA mutations and BRCAness in patients with metastatic breast cancer: Evidences from clinical trials</td>
</tr>
<tr>
<td></td>
<td>Y.-H. Im, KR</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:05</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>G. Pentheroudakis, GR</td>
</tr>
<tr>
<td>09:05 - 09:25</td>
<td>Hepatoma Case Presentation</td>
</tr>
<tr>
<td></td>
<td>C.-H. Koehne, DE</td>
</tr>
<tr>
<td>09:25 - 09:45</td>
<td>Hepatoma Case Discussion</td>
</tr>
<tr>
<td></td>
<td>S.P. Choo, SG</td>
</tr>
<tr>
<td>09:45 - 10:05</td>
<td>BRCA-related cancer syndromes: prevention, follow up, counselling Case Presentation</td>
</tr>
<tr>
<td></td>
<td>A. Trainer, AU</td>
</tr>
<tr>
<td>10:05 - 10:25</td>
<td>BRCA-related cancer syndromes: prevention, follow up, counselling Case Discussion</td>
</tr>
<tr>
<td></td>
<td>S.Y. Yoon, MY</td>
</tr>
<tr>
<td>10:25 - 10:30</td>
<td>Conclusions</td>
</tr>
<tr>
<td></td>
<td>A. Cervantes, ES</td>
</tr>
</tbody>
</table>
09:00 - 10:30  Type: Multidisciplinary tumour board  
Title: Challenges in the management of ALK positive stage III NSCLC  
Chair: Benjamin Solomon, AU; Suresh Senan, NL; Masahiro Tsuboi, JP

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:05</td>
<td>Presentation of case/condition</td>
<td>B. Solomon, VIC/AU</td>
</tr>
<tr>
<td>09:05 - 09:25</td>
<td>Medical oncologist’s perspective</td>
<td>B. Solomon, VIC/AU</td>
</tr>
<tr>
<td>09:25 - 09:45</td>
<td>Radiation oncologist’s perspective</td>
<td>S. Senan, NL</td>
</tr>
<tr>
<td>09:45 - 10:05</td>
<td>Thoracic surgeon’s perspective</td>
<td>M. Tsuboi, Chiba/JP</td>
</tr>
<tr>
<td>10:05 - 10:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
09:00 - 10:30  Type: Young Oncologist session
Title: Unusual challenges in clinical oncology: case discussions
Chair: Susana Banerjee, GB; Guillem Argilés Martinez, ES

09:00 - 09:05  Introduction

09:05 - 09:10  YO1 - Pulmonary Metastases From Anaplastic Meningioma Presenting with Non-Islet-Cell Tumour Hypoglycemia (NICTH) : A Case Report
N. Salimin¹, G.F. Ho²; ¹MY, ²Wilayah Persukutuan/MY

09:10 - 09:20  Q&A

R. Tan, S.J. Ong, M.H. Tan, M. Ng; SG

09:25 - 09:35  Q&A

09:35 - 09:40  YO3 - Hyperprogression after Immunotherapy in Non-clear cell RCC patient
T. Ruchakorn, TH

09:40 - 09:50  Q&A

09:50 - 09:55  Summary
**Type:** Mini Oral session  
**Title:** Mini Oral - Supportive and Palliative Care  
**Room:** 311

**Chair:** Kirsty Lee, HK; Carsten Bokemeyer, DE

09:00 - 09:05

**358O - Evaluation Of Functional Decline In Elderly Breast Cancer Patients Receiving First Line Chemotherapy**

Y. Khamis, A. Darwish, N. Lotfy, S. Abou-Raya, S.-E. Abdelmoneim; EG

09:05 - 09:10

**420O - The rate of Hepatitis B virus screening before systemic anticancer therapy among patients in Japan**

S. Yazaki, T. Yamauchi, T. Higashi; JP

09:10 - 09:15

**421O - Assessment and comparison of CISNE model versus MASCC model in clinically stable febrile neutropenia patients**

D. Koppaka\(^1\), L.C. Kuntegowdanahalli\(^2\), D. Lokanath\(^1\), K. Govind Babu\(^1\), L. Jacob\(^1\), M. Suresh Babu\(^1\), K.N. Lokesh\(^2\), A. Rudresha\(^2\), L. Rajeev\(^1\), S. Smitha\(^1\), A. Anand\(^1\), V. Asati\(^1\), R. Chethan\(^1\), R. Patidar\(^1\), T. Chaudhuri\(^1\), A. Kasturi\(^1\); \(^1\)IN, \(^2\)Karnataka/IN

09:15 - 09:20

**422O - A prospective phase III randomized study to evaluate the efficacy of olanzapine for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC).**

J. Pehalajani\(^1\), K. Govind Babu\(^1\), D. Lokanatha\(^1\), L. Jacob\(^1\), M. Suresh Babu\(^1\), K.N. Lokesh\(^2\), A. Rudresha\(^2\), L. Rajeev\(^1\), S. Smitha\(^1\), G. Giri\(^1\); \(^1\)IN, \(^2\)Karnataka/IN

09:20 - 09:25

**423O - Study of Psycho-social Profile of Caregivers In Teenage and Yound Adult (TYA) Cancer Patients: Indian Perspective**

D. Yadlapalli\(^1\), P. Chitalkar\(^2\), A. Punia\(^1\), S. Runu\(^1\), B. Ankit\(^1\); \(^1\)IN, \(^2\)MP/IN

09:25 - 09:45

**Discussion**

K. Lee\(^1\), C. Bokemeyer\(^2\); \(^1\)NSW/HK, \(^2\)DE
09:00 - 09:45

**Type: Mini Oral session**

**Title: Mini Oral - Public policy**

Chair: Deme Karikios, AU; Bishal Gyawali, US

---

**09:00 - 09:05**

**396O** - A multi-center, randomized, double-blind, parallel, two-group Phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

B. Han, K. Li, T. Chu, M. Bi, H. Zhang, Y. Yu, J. Shi, X. Zhang, Z. Chen, C. Han, T. Bai; CN

---

**09:05 - 09:10**

**397O** - Adolescents and Young Adults with Cancer Care in Asia: The Joint ESMO/SIOPE/SIOP ASIA survey


---

**09:10 - 09:15**

**398O** - The Prevalence of Breast Tumor: An Indonesia Non Communicable Disease Survey

S. Idaiani, D. Delima; ID

---

**09:15 - 09:20**

**399O** - Analysis of the Current Status of Multidisciplinary Team (MDT) Care for Cancer Patients in Korea


---

**09:20 - 09:40**

**Discussion**

D. Karikios1, B. Gyawali2; 1NSW/AU, 2Aichi/US
09:55 - 10:00  **87O - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Analysis from two prospective trials**


10:00 - 10:05  **88O - Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial**


10:05 - 10:15  **Discussion**

D. Goldstein, NSW/AU

10:15 - 10:20  **153O - M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype**

C. Yoo¹, D.-Y. Oh², H.J. Choi², M. Kudo³, M. Ueno³, S. Kondo³, L.-T. Chen⁴, M. Osada³, C. Helwig⁵, I. Dussault⁶, M. Ikeda³; ¹Songpa-gu/KR, ²KR, ³JP, ⁴TW, ⁵DE, ⁶MA/US

10:20 - 10:25  **154O - Atezolizumab monotherapy in Chinese patients with locally advanced or metastatic solid tumours**

L. Shen, L. Zhang, X. Hu, H. Pan, T. Liu, Y. Bai, Y.-C. Chen, J. Huang, T. Xu, W. Hsu, J. Shi; CN

10:25 - 10:30  **155O - Efficacy of TAS-120, an Irreversible Fibroblast Growth Factor Receptor Inhibitor (FGFRI), in Patients With Cholangiocarcinoma and FGFRI Pathway Alterations Previously Treated With Chemotherapy and Other FGFRI’s**


10:30 - 10:45  **Discussion**

B. Ma, HK
### Type: Mini Oral session

**Title: Mini Oral - Developmental and precision medicine**

Chair: Miguel Quintela-Fandino, ES; Daniel Shao Weng Tan, SG; Timothy Yap, US; Nicholas McGranahan, GB

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:55 - 10:00</td>
<td>70O - Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients</td>
</tr>
<tr>
<td>10:00 - 10:05</td>
<td>71O - Phase 1 extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours.</td>
</tr>
<tr>
<td></td>
<td>D. Tan¹, M. Ng¹, V. Subbiah², W. Messersmith³, V. Teneggi⁴, V. Diermayr¹, K. Ethirajulu¹, P. Yeo¹, B.H. Gan¹, L.H. Lee¹, S. Blanchard¹, R. Nellore¹, M. Yasin¹, D. Umrani¹, M.A. Lee¹, J. Hill¹, B. Madan¹, D. Virshup¹, A. Matter¹; ¹SG, ²TX/US, ³CO/US, ⁴Singapore/SG</td>
</tr>
<tr>
<td>10:05 - 10:10</td>
<td>72O - Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): safety, efficacy and biomarkers.</td>
</tr>
<tr>
<td></td>
<td>M. Quintela-Fandino¹, L. Manso Sánchez¹, E. Holgado Martín¹, M. Moreno¹, S. Morales Murillo², B. Bermejo De Las Heras³, D. Malon Gimenez¹, R. Colomer Bosch¹, L. Gonzalez Cortijo⁴, J. Hornedo¹, S. Mouron¹, M. Muñoz¹, S. Escudero¹, R. Blanco¹, S. Mañes¹; ¹ES, ²NA, ³Valencia/ES, ⁴Madrid/ES</td>
</tr>
<tr>
<td>10:10 - 10:20</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>D.S.W. Tan¹, T. Yap²; ¹SG, ²Surrey/US</td>
</tr>
<tr>
<td>10:20 - 10:25</td>
<td>367O - Parallel identification and profiling of tumour antigen-specific T cells for biomarker discovery by mass cytometry</td>
</tr>
<tr>
<td></td>
<td>F. Michael, E. Newell; SG</td>
</tr>
<tr>
<td>10:25 - 10:30</td>
<td>368O - Tumor mutation index as biomarker for responsive stratification on multi-targeted TKI Anlotinib: an ALTER-0303 companion diagnostic study</td>
</tr>
<tr>
<td></td>
<td>J. Lu, W. Zhang, B. Yan, H. Li, L. Zhang, Y. Dong, J. Qian, S. Wang, B. Zhang, J. Wu, X. Zhao, Y. Zhao, B. Han; CN</td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td>369O - Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Ph2 umbrella trial in China (CTONG1505)</td>
</tr>
<tr>
<td></td>
<td>O. Zhou¹, X.-C. Zhang², H.-Y. Tu², B. Gan², B.-C. Wang², C.-R. Xu², H.-J. Chen², M.-Y. Zheng², Z. Wang², X.-Y. Bai², Y.-L. Sun², A. Myers², X. Lv², Y. Chakrabarti³, S. Zhao², J.-J. Yang², Y.-L. Wu²; ¹Guangdong/CN, ²CN, ³IN</td>
</tr>
<tr>
<td>10:35 - 10:45</td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>M. Quintela-Fandino¹, N. McGranahan²; ¹ES, ²GB</td>
</tr>
</tbody>
</table>

Last update: 09-11-2018 02:52:09pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 11:00</td>
<td>Young Oncologist session</td>
<td>Meet your mentor</td>
<td>Exhibition area</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>Proffered Paper session</td>
<td>Presidential Symposium</td>
<td>Hall 406</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Josep Taberner, ES; Andrés Cervantes, ES</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>LBA1 - IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)</td>
<td>T.S.K. Mok¹, M. Reck², L. Horn³, S. Lam⁴, D. Shames⁴, J. Liu⁵, F. Kabbinavar⁴, W. Lin⁴, A. Sandler⁶, S. Liu⁷; ¹HK, ²DE, ³TN/US, ⁴US, ⁵CN, ⁶OR/US, ⁷DC/US</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Invited discussant</td>
<td>P. Garrido Lopez, ES</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>LBA2 - Primary results of ALESIAY: phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)</td>
<td>C. Zhou¹, Y. Lu², S.-W. Kim³, T. Reungwetwattana⁴, J. Zhou¹, Y. Zhang¹, J. He¹, J.-J. Yang¹, Y. Cheng³, S.H. Lee³, L. Bu¹, T. Xu¹, L. Yang¹, C. Wang¹, P. Morcos⁶, E. Mitry⁷, Z. Li⁸; ¹CN, ²Sichuan/CN, ³KR, ⁴TH, ⁵Jilin/CN, ⁶NY/US, ⁷CH, ⁸Guangdong/CN</td>
<td></td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Invited discussant</td>
<td>R. Soo, SG</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td>LBA3 - Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial</td>
<td>M. Friedlander¹, K. Moore², N. Colombo³, G. Scambia³, B.-G. Kim⁴, A. Oaknin⁵, A. Lisyanskaya⁶, A. Floquet⁷, A. Leary⁸, G. Sonke⁹, C. Gourley¹⁰, S. Banerjee¹⁰, A. Oza¹¹, A. González-Martín⁵, C. Aghajanian¹², W. Bradley¹³, E. Lowe¹⁴, R. Bloomfield¹⁰, P. Disilvestro¹⁵; ¹NSW/AU, ²US, ³IT, ⁴KR, ⁵ES, ⁶RU, ⁷CEDEX/FR, ⁸FR, ⁹NL, ¹⁰GB, ¹¹Ontario/CA, ¹²NY/US, ¹³WI/US, ¹⁴MD/US, ¹⁵RI/US</td>
<td></td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>Invited discussant</td>
<td>A.M. Poveda Velasco, ES</td>
<td></td>
</tr>
</tbody>
</table>

Last update: 09-11-2018 02:52:09pm
12:45 - 12:50 Welcome introduction
R. de Wit, NL

12:50 - 13:05 Definition and peculiarities of CRPC: M0 vs M1
M. De Santis, DE

13:05 - 13:20 Chemotherapy in mCRPC: Is it still relevant?
B. Tran, AU

13:20 - 13:35 Hormonal therapies in mCRPC: Where are we now?
R. de Wit, NL

13:35 - 13:50 Is there an optimal sequencing strategy in mCRPC?
M. De Santis, DE

13:50 - 13:55 Immunotherapy in mCRPC: Moving beyond Sip-T
T. Powles, GB

13:55 - 14:15 Conclusion and wrap up
B. Tran, AU

14:30 - 14:55 Metastatic prostate cancer: Optimal use of the currently available agents
R. de Wit, NL

14:55 - 15:20 Renal cell cancer: Optimising systemic treatment in an era of emerging treatment paradigms
M. Lolkema, NL

15:20 - 15:45 Integration of immunotherapy in bladder cancer: Who and when to treat?
M. De Santis, DE

15:45 - 16:00 Discussion
14:30 - 16:00  Type: Joint Symposium  
Title: ESMO-AACR: PD1/PDL1: From discovery to clinical use  
Chair: Solange Peters, CH; Thomas Powles, GB

14:30 - 14:35  Introduction  
T. Powles, GB

14:35 - 14:55  Discovery of immune checkpoint as a mechanism of immune suppression  
P. Romero, CH

14:55 - 15:15  Predictive biomarker of efficacy for the use of immune checkpoint inhibitors  
T. Powles, GB

15:15 - 15:35  Development in the use of immune checkpoint inhibitors: Lung cancer as a paradigm shift  
S. Peters, CH

15:35 - 15:55  Should immune checkpoint inhibitors be considered as agnostic drugs?  
J. Larkin, GB

15:55 - 16:00  Conclusions  
S. Peters, CH

14:30 - 16:00  Type: Multidisciplinary tumour board  
Title: Multidisciplinary approach to resectable gastric cancer  
Chair: Florian Lordick, DE; Masanori Terashima, JP

14:30 - 14:35  Presentation of case/condition  
F. Lordick, DE

14:35 - 14:55  Surgical treatment perspectives  
M. Terashima, Shizuoka/JP

14:55 - 15:15  Medical oncology perspectives  
S.P. Choo, SG

15:15 - 15:35  Is there a role for radiotherapy?  
T. Leong, AU

15:35 - 16:00  General discussion

Last update: 09-11-2018 02:52:09pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:40</td>
<td>Case presentation</td>
<td>U. Wedding, DE</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td>Assessment by onco-geriatrician</td>
<td>U. Wedding, DE</td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td>Balancing between treatment and toxicity</td>
<td>C. Steer, VIC/AU</td>
</tr>
<tr>
<td>15:20 - 15:40</td>
<td>Managing the financial implication</td>
<td>D. Keefe, SA/AU</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>Conclusions</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Type</td>
<td>Title</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>14:30 - 15:15</td>
<td>Mini Oral session</td>
<td>Mini Oral - Breast cancer</td>
</tr>
<tr>
<td>14:35 - 14:40</td>
<td>2O - Implications of Plasma Deoxyribonucleic Acid Topoisomerase 2 Beta Level in Breast Cancer Patients receiving Doxorubicin-Based Chemotherapy</td>
<td>T. Win, T.T. Naing, T.T. Win, K.K. Aung, Y.Y. Htun; MM</td>
</tr>
<tr>
<td>14:45 - 14:50</td>
<td>41O - Decreased mortality strongly correlated with the upregulation of BCR in breast cancer metastasis to bone</td>
<td>S.N. Mai, H. Vu, X.T. Hoang, V.T. Than, T. Nguyen, M.T. Le, P.-L. Luu, H. Tran, M.N. Nguyen; 1VN, 2WA/AU, 3KR, 4ACT/AU, 5US</td>
</tr>
<tr>
<td>14:50 - 15:15</td>
<td>Discussion led by moderators</td>
<td></td>
</tr>
<tr>
<td>14:30 - 16:00</td>
<td>Educational session</td>
<td>The reality of accessing cancer care in Asia and Asia/Pacific</td>
</tr>
<tr>
<td>14:30 - 14:55</td>
<td>Cancer medicines: What is available and is it effective enough?</td>
<td>A. Eniu, RO</td>
</tr>
<tr>
<td>14:55 - 15:20</td>
<td>Financial toxicity of cancer treatment in Asia and Asia-Pacific</td>
<td>M. Bertram, CH</td>
</tr>
<tr>
<td>15:20 - 15:45</td>
<td>Strategies to improve accessibility and availability of cancer medicines in LMICs</td>
<td>S. Thongprasert, Muang/TH</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

Last update: 09-11-2018 02:52:09pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:20</td>
<td>Mini Oral session</td>
<td>Mini Oral - Head and neck cancers</td>
<td>Anthony Chan, HK; Joseph Wee, SG</td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td>304O</td>
<td>Relationship of Circulating Tumor Cells to Progression-Free Survival and Tumor Response in Patients with Metastatic Nasopharyngeal Carcinoma: A Prospective Cohort Study</td>
<td>R. You¹, M. Chen², Y.-P. Liu¹, Y.-N. Zhang¹, P.-Y. Huang¹; ¹CN, ²Guangdong/CN</td>
</tr>
<tr>
<td>15:35 - 15:40</td>
<td>305O</td>
<td>Surgery for Isolated Regional Failure in Nasopharyngeal Carcinoma after Radiation: Selective or Comprehensive Neck Dissection</td>
<td>L. You-Ping¹, R. You¹, M. Chen², H. Li¹; ¹CN, ²Guangdong/CN</td>
</tr>
<tr>
<td>15:40 - 15:50</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:50 - 15:55</td>
<td>307O</td>
<td>Randomized, double-blind, placebo-controlled trial of probiotics to reduce radiation and chemotherapy induced oral mucositis for nasopharyngeal cancer patients</td>
<td>C. Jiang, H. Xie, L. Zeng, T. Chen, J. Li; CN</td>
</tr>
<tr>
<td>15:55 - 16:05</td>
<td>Discussion led by moderators</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Exhibition area</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:30</td>
<td>Young Oncologist session</td>
<td>Meet your mentor</td>
<td></td>
</tr>
</tbody>
</table>

Last update: 09-11-2018 02:52:09pm
16:30 - 18:00  Type: ESMO Clinical Practice Guidelines session  
Title: Adaptation of ESMO guidelines in Asia  
Chair: Josep Tabernero, ES; Takayuki Yoshino, JP

16:30 - 16:40  Welcome and Introduction  
T. Yoshino\textsuperscript{1}, J. Tabernero\textsuperscript{2}; \textsuperscript{1}JP, \textsuperscript{2}ES

16:40 - 16:55  Case presentation: Metastatic oeso-gastric cancer  
T. Nakajima, JP

16:55 - 17:10  Pan Asia Adapted metastatic Oeso-Gastric cancer Guidelines: results  
K. Muro, Aichi/JP

17:10 - 17:25  Case presentation: Metastatic Non-Small Cell Lung Cancer  
H. Sun, CN

17:25 - 17:40  Pan Asia Adapted metastatic NSCLC cancer Guidelines: results  
Y.-L. Wu, CN

17:40 - 18:00  The way forward: other ESMO guidelines to adapt in 2019 Perspective and Challenges (panel), moderated by George Pentheroudakis  
G. Pentheroudakis, GR

16:30 - 18:00  Type: Special Session  
Title: In collaboration with ATEP: Pulmonary ground glass opacities (GGOs): Emerging challenge, evolving management  
Chair: Tetsuya Mitsudomi, JP

16:30 - 16:45  GGO Management: Are current guidelines adequate?  
T. Mitsudomi, JP

16:45 - 17:05  Advances in clinical and molecular profiling of GGOs

17:05 - 17:25  Resection of GGOs: Are surgeons being too aggressive ... or not aggressive enough?  
S. Cho, KR

17:25 - 17:45  Advances in techniques and technologies for GGO surgery  
A.D.L. Sihoe, HK

17:45 - 18:00  Discussion and Conclusions
16:30 - 18:00  Type: Educational session  Title: Neurotoxicity: A problem to remember  Chair: Dorothy Keefe, AU; Kirsty Lee, HK

16:30 - 16:55  Peripheral neuropathy  
G. Cavaletti, IT

16:55 - 17:20  Lost in the fog: What is chemobrain?  
F. Boyle, AU

17:20 - 17:45  Acute central neurotoxicity  
K.A. Griffith, US

17:45 - 18:00  Discussion

16:30 - 19:00  Type: Special Session  Title: Radiation oncology  Room 324  Chair: Françoise Mornex, FR; Suresh Senan, NL

16:30 - 16:42  Stage III NSCLC and the immuno-oncology paradigm: Immunotherapy  
R. Soo, SG

16:42 - 16:54  Stage III NSCLC and the immuno-oncology paradigm: Radiotherapy considerations  
F. Mornex, CEDEX/FR

16:54 - 17:00  Q&A

17:00 - 17:12  Approaches towards inoperable HCC: Systemic treatment of HCC  
S.P. Choo, SG

17:12 - 17:24  Approaches towards inoperable HCC: Role of external beam radiotherapy evidence and comparison with other local treatment  
J. Seong, KR

17:24 - 17:30  Q&A

17:30 - 17:42  Evolving radiotherapy strategies in early-stage breast cancer: The role of surgery and new surgical approaches in early breast cancer  
C.W. Chan, SG
Evolving radiotherapy strategies in early-stage breast cancer: The role of radiotherapy and new technical approaches
F. Lim, SG

Q&A

Oesophagus and Oeso-gastric junction carcinomas: Role of systemic treatment
F. Lordick, DE

Oesophagus and Oeso-gastric junction carcinomas: The radiation oncologist point of view
T. Leong, AU

Q&A

Oligometastatic prostate cancer - Management options: Initial neo-adjuvant systemic treatment
R. Kanesvaran, SG

Oligometastatic prostate cancer - Management options: The radiation oncologist point of view
M.L.K. Chua, SG

Q&A
16:30 - 16:35  **2120 - United in Fight against prOstate cancer registry (UFO): treatment patterns and quality of life from a large, multi-center, longitudinal cohort study in Asia**

R. Kanesvaran¹, H. Uemura², D. Ye³, E. Chiong¹, B. Lojanapiwat⁴, Y.-S. Pu⁵, S. Kumar Rawal⁶, A.H.A. Razack⁷, H. Zeng³, B.H. Chung⁸, Y.-S. Tsai⁹, M.Y. Noor Ashani⁷, Y. Liu⁹, M. Asinas-Tan¹, W. Liu³, G.K.M. Low¹, M. van Kooten Losio¹⁰; ¹SG, ²JP, ³CN, ⁴TH, ⁵TW, ⁶IN, ⁷MY, ⁸KR, ⁹NJ/US, ¹⁰ACT/AU

16:35 - 16:40  **2130 - Efficacy and Safety of Apalutamide (APA) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN: Asian Subpopulation**

P. Mainwaring¹, E. Small², H. Uemura³, J.Y. Lee⁴, S.-T. Pang⁴, G. Marx¹, T.G. Kwon⁴, T. Satoh³, A. Bhaumik⁵, S. Cheng⁵, A. Londhe⁶, A. Lopez-Giltlitz², M. Smith⁷; ¹ACT/AU, ²CA/US, ³JP, ⁴KR, ⁵NJ/US, ⁶PA/US, ⁷US

16:40 - 16:45  **2140 - The change in expression of prostate-specific membrane antigen in circulating tumor cells during treatments for castration-resistant prostate cancer**

N. Nagaya, M. Kanayama, M. Nagata, S. Horie; JP

16:45 - 16:50  **2320 - Pharmacokinetics of Cabozantinib in Asian and Non-Asian Populations**

F. Benzaghou¹, T.X.Q. Nguyen¹, S. Lacy²; ¹FR, ²CA/US

16:50 - 16:55  **2330 - Real World Practice and Outcomes for Metastatic Renal Cell Carcinoma: What Can We Learn from Real World Data Analysis in the US?**

F. Benzaghou¹, A. Ren², M. del Pilar Schneider¹, J. Dinet¹, E. Pham¹; ¹FR, ²MA/US

16:55 - 17:15  **Discussion led by moderators**
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:45</td>
<td>Special Session</td>
<td>The pathology, molecular biology and management of early ovarian cancer</td>
<td>310</td>
<td>S. Banerjee, GB</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td>Special Session</td>
<td>The management of advanced and recurrent ovarian cancer</td>
<td>310</td>
<td>J. Ledermann, London/GB</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td>Special Session</td>
<td>The Asian perspective</td>
<td>310</td>
<td>D. Tan, SG</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td>Special Session</td>
<td>Discussion / Q&amp;A</td>
<td>310</td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:15</td>
<td>Mini Oral session</td>
<td>Type: Mini Oral session - Gynaecological cancers</td>
<td>311</td>
<td></td>
</tr>
<tr>
<td>17:35 - 17:40</td>
<td>Mini Oral session</td>
<td>254O - Dysgerminoma Ovary: Clinical Features and Treatment Outcome</td>
<td>311</td>
<td>P. Nair, A. Kumar, S. Mathews, J. Joseph, S. Suchetha, J. Krishna, F. James; IN</td>
</tr>
<tr>
<td>17:45 - 17:50</td>
<td>Mini Oral session</td>
<td>256O - Barriers to early diagnostics of cervical cancer in Uzbekistan</td>
<td>311</td>
<td>V. Saidakhmedova, N. Zakhirova, E. Osmanova, O. Akhmedov, B. Yusupov, S. Djanklich, D. Egamberdiev; UZ</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>Poster Display</td>
<td>Breast cancer, early stage</td>
<td>Exhibition area</td>
<td></td>
</tr>
</tbody>
</table>
3P - HER2 positive rates in Invasive Lobular Breast Carcinoma: A study amongst 1,095 consecutive Asian patients

4P - CanAssist-breast - an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia
M. Bakre, Karnatala/IN

5P - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial
S. Elyasi1, H. Karbasforushan1, S. Hosseini2, A. Fani Pakdel1; 1IR, 2Khorasan Razavi/IR

6P - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery
K. Periasamy, S. Cholayil, G. Karunanithi, K. Dharianipragada, V. Neelakandan; IN

7P - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review
J.G. Pandy, J. Balolong-Garcia, M.V. Cruz-Ordinario, F.V. Que; PH

8P - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer
W. Yeo, Y. Lei, A. Cheng, C. Kwok, K. Cheung, R. Lee, I. Lee, Y. He, S. Ho; HK

9P - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay
H. Xie, J. Lövrot, J. Lindh, J. Bergh, S. Sim; SE

10P - A novel nipple areolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer
H. Seki, T. Sakurai, K. Shimizu; JP

11P - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
T.H. Kim, G. Gwak, M.S. Chung, J.I. Kim, I. Park, E. Um, J.W. Han, A. Lee; KR

12P - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer
O. Cho, Y.-T. Oh; KR

13P - Upgrade of Low Grade Ductal Carcinoma in situ (DCIS): multimodality approach in a 10-year single institution study
A. Chu, J.M. Chang, W.K. Moon; KR
18:00 - 18:00  **14P - Correlation between circulating tumor cells and the aromatase inhibitors therapy in postoperative patients with early breast cancer**
Y. Shi, G. Zhang, Y. Wang, C. Ren, L. Wen, L. Guo, N. Liao; CN

18:00 - 18:00  **15P - A Pilot Study of Single Pegfilgrastim Compared with Intermittent Every Other Days of 5 Shot-filgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Chemotherapy (G-CSF 105 trial: NCT02685111)**

18:00 - 18:00  **17P - Painful scalp during chemotherapy induced hair loss is associated to permanent alopecia in breast cancer patients**
N. Mejri, M. Saadi, F. Guermazi, H. El Benna, N. Daoud, S. Labidi, H. Boussen; TN

18:00 - 18:00  **18P - Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran**
S. Pashaei, R. Dolatkhah, Z. Sanaat, P. Jabbaripour, G. de Bock; 1IR, 2East Azerbaijan/IR, 3NL

18:00 - 18:00  **19P - Is sarcopenia associated with increased toxicity of neoadjuvant/adjuvant chemotherapy for breast cancer?**
A. Ueno, K. Yamaguchi, M. Sudo, S. Imai; JP

18:00 - 18:00  **20P - A Study on possibility of High Sensitivity C-reactive protein (hs-CRP) and Circulating Interleukin-6 (IL-6) as biomarker in Breast Cancer Patients**
M.S.J.R. Shahi, M. Dey, A. Chowdhury; BD

18:00 - 18:00  **21P - Correlation Between Expression of Topoisomerase II Alpha with Ki-67 and Tumor Size in Luminal B-Like Indonesian Breast Cancer Patients**
H. Putri, M. Kristina, D. Widjaja, B. Baskoro, E. Kristiani; ID

18:00 - 18:00  **22P - Association of Serum Vitamin D Level and Vitamin D Receptor Polymorphism (Apa 1) And Breast Cancer**
S. Gohar, S. Al-Hassanin, B. Montaser, S. Soliman; 1Menoufia Governorate/EG, 2EG

18:00 - 18:00  **Breast cancer, locally advanced**

18:00 - 18:00  **24P - Prognostic Nomograms for Predicting Overall and Cancer-Specific Survival in Breast Cancer Patients Not Achieving Pathological Complete Response After Neoadjuvant Chemotherapy**

18:00 - 18:00  **25P - Prognostic Nomogram Based on Lymph Node Ratio to Predict Survival in Node-Positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy**
26P - Breast tumor associated exosomes mediate loss of antitumor immune response by arresting cytotoxic T cell functions in the tumor microenvironment
S. Chatterjee, A. Chatterjee, S. Jana, H. Roy, N. Nargis, A. Bhattacharyya; IN

27P - Hormonal therapy confers clinically relevant benefit in women with low estrogen receptor-positive breast tumor
T. Zhang, B. Ho, P. Chan, E.Y. Tan; SG

28P - Breast board combined with a thermoplastic head mask immobilization can improve the reproducibility of the treatment setup for breast cancer patients who received whole breast and supraclavicular nodal region irradiation
M.W. Ma, S. Wang, S. Qin; CN

29P - Imaging-proven Venous Thromboembolism Breast Cancer in a Tertiary Hospital in the Philippines
A.T. Gerona, PH

30P - Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) : Single center experience

31P - PD-L1 expression on circulating monocytes in patients with breast cancer
M. Nagano, K. Saito, Y. Kozuka, M. Shibusawa, N. Imai, A. Noro, Y. Kageyama, T. Mizuno, T. Ogawa, N. Katayama; JP

32P - Dosimetric plan evaluation of hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) and 2-Dimensional (2D) simulator planning in whole breast irradiation after breast conserving surgery
M. Roy, B. Goswami, S. Goswami, A. Jadhav, S. Agarwal; IN

33P - IQGAP3 Overexpression Correlates with Poor Prognosis and Radiation Therapy Resistance in Breast Cancer

34P - A reliable nomogram for predicting overall survival in patients with triple-negative breast cancer
M.W. Ma, N. Jing, S. Gao; CN

35P - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy
U. Velu, P. Alurkar; IN
18:00 - 18:00  **36P - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?**
K. Taroeno-Hariadi, M. Hardianti, J. Kurnianda, Y. Putra, T. Aryandono; ID

18:00 - 18:00  **37P - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast Cancer in Sanglah General Hospital, Bali**
A.A. Lestari, I.P. Prabawa, S. Wiranata, I.G.P. Supadmanaba; ID

18:00 - 18:00  **YO4 - Breast ecchymotic purpura: a rare presentation of a locally advanced breast carcinoma**
C. Dabiri, K. Wehbe, O. Hu, P. Soibinet Oudot; FR

18:00 - 18:00  **Breast cancer, metastatic**

18:00 - 18:00  **42P - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)**
N. Masuda1, S. Noguchi1, T. Ishikawa1, T. Aruga1, S.J. Kim1, T. Toyama1, T. Saeki1, M. Saito1, T. Yamanaka1, J. Watanabe1, S. Nakamura1, M. Takahashi1, K. Inoue1, I. Gounaris2, Y. Han2, T. Samant2, M. Gazdoiu2, Y. Ito1; 1JP, 2NJ/US

18:00 - 18:00  **43P - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer**
M. Elbaiomy1, M. El-Ghonemy2, R. Elhelaly2, R. Elzehery2; 1Mansura/EG, 2EG

18:00 - 18:00  **44P - Global Clinical Trials Validating Bioequivalence with China-Manufactured Trastuzumab Biosimilar, HLX02, and Herceptin®**
Q. Zhang1, B. Xu1, Q. Zhang1, T. Sun1, W. Li1, Y. Teng1, X. Hu1, I. Bondarenko2, H. Adamchuk2, L. Zhong1, D. Trukhin2, S. Wang1, H. Zheng1, Z. Tong1, X. Zhang1, E. Liu1, W. Jiang1, S. Liu1, A. Lok1; 1CN, 2UA

18:00 - 18:00  **45P - Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s**
Y. He, J. Tang; CN

18:00 - 18:00  **46P - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.**
A. Anand1, L. Jacob1, K.C. Lakshimaiah1, K. Govind Babu1, D. Lokanatha1, M. Suresh Babu1, K.N. Lokesh2, A.H. Rudresha1, L. Rajeev1, S. Saldanha1, G. Gir1, R. Patidar1, V. Asati1, R. Chethan1, T. Chaudhuri1, D. Koppaka1, D. Panwar1, R. Kumar1; 1IN, 2Karnataka/IN

18:00 - 18:00  **47P - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast Cancer**
18:00 - 18:00 48P - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients
S.S. Kang, KR

18:00 - 18:00 49P - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells
X. Chen, J. Tang; CN

18:00 - 18:00 50P - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443
J. Hou, J. Tang; CN

18:00 - 18:00 51P - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer
S. Nandi, R. Bhattacharya, T. Roychowdhury, U. Roy, S. Chattopadhyay, A. Mukhopadhyay; IN

18:00 - 18:00 52P - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea

18:00 - 18:00 53P - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers
S. Rajarajan, J. Prabhu, A. Korlimarla, M. Nair, A. Alexander, R. Kaluve, H. Ps, U. Raja, R. Ramesh, S. Patil, S. Bs, S. Ts; IN

18:00 - 18:00 54P - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer
Y. Li, Y. Wang; CN

18:00 - 18:00 55P - Quality of life and psychosocial needs of metastatic breast cancer patients
T. Mehmood, PK

18:00 - 18:00 56P - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells
Y. Shen, L. Zhang, H. Zhao, C.-L. Shen; CN

18:00 - 18:00 57P - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation
M. Wang, J. Tang; CN

18:00 - 18:00 58P - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience
**59P - Proteolysis-Targeting Chimera (PROTAC) Compounds to Degrade S100A4 and Inhibit Breast Cancer Metastasis**

M. Du, G. Wang, T. Ismail, R. Crick, R. Barraclough, B. Daimark, G. Nixon, P. Rudland; GB

**CNS tumours**

**60P - Most clinically approved anti-EGFR antibodies fail to neutralize EGFRvIII, leading to lack of anti-tumour efficacy in high grade glioma**

S. Greenall, T. Adams, T. Johns; 1AU, 2VIC/AU, 3WA/AU

**61P - Regulation of Programmed cell death 10 (PDCD10) by FAT1 gene in human glioblastoma**

N. Malik, P. Chattopadhyay, C. Sarkar, A. Suri, S. Sinha, K. Chosdol; IN

**62P - Overall survival of elderly glioblastoma patient treated with concurrent chemoradiotherapy: A retrospective review with comparison to non-elderly counterpart**

A. Das, BD

**64P - Association of MTHFR gene polymorphisms with glioma and meningioma patients in Indian population**

R. Kumawat, S. Gowda, E. Debnath, S. Rashid, R. Niwas, A. Suri, C. Sarkar, S. Sinha, K. Chosdol; IN

**66P - A phase II trial of response adapted whole brain radiotherapy after high dose Methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma**

N. Adhikari, A. Biswas; IN

**67P - Association between altered expression of key enzymes involved in kynurenine pathway with clinical outcome in patients with different grades of astrocytoma**


**68P - Triple intrathecal chemotherapy for leptomeningeal carcinomatosis in solid tumours**

V. Srinivasalu, N. Subramaniam, A. Philip, W. Jose, K. Pavithran; 1IN, 2Tamil Nadu/IN, 3Kerala/IN

**YO5 - Pleural metastasis from anaplastic meningioma**

T. Patimarattananan, T. Ativitas; TH
YO6 - Pituitary and pineal germinoma with peritoneal metastasis
C. Ngokngarm, C. Bandidwattanawong, A. Suthepwanon, K. Runglodvatana; TH

YO7 - Pulmonary metastases in recurrent intracranial meningioma: Case Report
A.A. Sulaiman Shah, F. Ismail; MY

Developmental therapeutics

73P - Ganoderic acids BT-01, a galectin-1 inhibitor, suppresses ovarian cancer growth in humanized mouse xenograft model.

77P - SMA-tDodSNO improves the potency of doxorubicin in breast cancer evidence for the involvement of oxidative stress
H. Alimoradi1, A. Barzegarfallah1, K. Giresh2; 1NZ, 2BH

78P - Selective killing of circulating tumor cells prevents metastasis and extends survival
Y.R. Kim, J.W. Choi; KR

79P - CXCR4 antagonist mediated targeting of cancer cells using nanoparticles
S. Ansari, M. Mudassir, B. Vijayalekshmi, P. Chattopadhyay; IN

80P - Emodin Sensitizes Ovarian Cancer Cells to Carboplatin through Suppression of Mitochondrial Respiration
Y. Ge, Y. Chen, W. Wang, D. Wu, F. Cao, X. Zhou, J. Gao, Z. Cao, X. Zheng, W. Li, J. Li; CN

81P - NKG2D enhances chemosensitivity to cisplatin in patients with extensive small cell lung cancer by up-regulating NF-κβ2
R. Si, G. Yang, X. Tang; CN

82P - Anticancer activity of Moringa Oleifera mediated Silver Nanoparticles (AgNps) on Human Lymphocyte Cells
S. Mahalakshmi, IN

83P - Phase 1 Investigator’s Perceptions to ‘Supersized Seamless Trials in Oncology’
B. Ma1, N. van der Velden2, F. Mo1, H. Loong1, L. Siu3, B. Goh4, Y.-J. Bang5, C.-C. Lin6, J. Desai7, M. Lolkema2; 1HK, 2NL, 3Ontario/CA, 4SG, 5KR, 6TW, 7VIC/AU

84P - Real World Experience of adverse events with immunotherapy using PD1 inhibitors- Single center experience from India
A. Rauthan1, P. Patill1, S.P. Somashekhar1, S. Zaveri2; 1IN, 2Karnataka/IN
18:00 - 18:00  **85TiP** - A Phase 1 trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer

S. Kitano¹, T. Shimizu¹, T. Koyama¹, T. Ebata¹, S. Iwasa¹, S. Kondo¹, A. Shimomura¹, Y. Fujiwara¹, N. Yamamoto¹, C. Bauml², S. Li³, P. Rietschel², T. Sims²; ¹JP, ²NY/US, ³NJ/US

18:00 - 18:00  **Gastrointestinal tumours, colorectal**

D. Goldstein, NSW/AU

18:00 - 18:00  **89P** - Prevention and Management of Low Rectal Anastomotic Leakage in The Robotic Era: A Propensity Score Matched Study

J. Xu, W. Chang, Y. Wei, T. Liu; CN

18:00 - 18:00  **90P** - Robot-assisted versus laparoscopic surgery for colorectal Cancer: short-term outcome of a retrospective comparative study

L. Li, X. Yang, X. Zhu, W. Zhang, L. Feng, B. Du; CN

18:00 - 18:00  **91P** - Surgery versus Combined Surgery and Chemotherapy: Survival Patterns among Patients with Stage II Colorectal Adenocarcinoma

A. Shaltout, N. Sayed, A. Obobakr, R. Elemam, I. Uthman; EG

18:00 - 18:00  **92P** - NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons.

I. Iwanaga¹, S. Yuki², Y. Kawamoto¹, H. Nakatsumi¹, N. Takahashi¹, T. Shichinohe¹, H. Okuda², A. Ishiguro¹, K. Harada¹, K. Hatanaka², K. Oomori¹, M. Nakamura¹, N. Senmaru¹, K. Iwai¹, M. Koike¹, Y. Ito¹, A. Taketomi¹, S. Hirano¹, N. Sakamoto¹, Y. Komatsu²; ¹JP, ²Hokkaido/JP

18:00 - 18:00  **93P** - Maintenance therapy with monthly tegafur-uracil for improving disease-free survival of patients with ypStage III rectal cancer

Y.H. Kuo, TW

18:00 - 18:00  **94P** - Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer


18:00 - 18:00  **95P** - Long term outcomes of preoperative concurrent CapeOx/RT in locally advanced rectal cancer

E. Sirachainan, C. Sitathanee, W. Suwanthanma, N. Larbcharoensub, S. Lukrak, N. Sripaiboonkit Thokanit, S. Phongkitkarun, K. Sumboonnanonda; TH
96P - Efficacy and safety of S-1-based chemotherapy as first-line treatment in colorectal cancer: a meta-analysis of randomized controlled trials
Z. Wang, Y. Zang, X. Liu, G. Zhang, G. Cheng; CN

97P - Is right-sided (sRt) BRAF mutated (mBRAF) metastatic colorectal cancer (mCRC) unresponsive to the 1st-line antiEGFR antibody treatment?
R. Kudo, JP

98P - The role of perioperative radiotherapy for patients with local recurrence of rectal cancer
H. Karasawa1, S. Ohnuma1, H. Suzuki1, A. Kohyama1, K. Watanabe1, T. Kamei1, T. Naitoh1, M. Unno2; 1JP, 2Miyagi/JP

99P - Comparative study: Side effects of Folfox4 and Folfiri for Colorectal Cancer Chemotherapy regimen in Margono Soekarjo Hospital, Purwokerto

100P - Phase 2 KEYNOTE-164 Study of Pembrolizumab (pembro) Monotherapy for Patients (pts) With Previously Treated, Mismatch Repair–Deficient (dMMR) Advanced Colorectal Cancer (CRC): Primary and Japan Subgroup Analyses
H. Hara1, T. Yoshino1, H. Taniguchi2, K. Akagi1, K. Shitara1, T. Masuishi2, Y. Kuboki1, T. Shimamoto1, K. Ueki1, S.R. Han1, K. Noguchi3, L. Diaz4; 1JP, 2Aichi/JP, 3Chiyoda-ku/JP, 4MD/US

101P - Effect On Oxaliplatin-Free Interval For Successful Rechallenge Of Oxaliplatin In Colorectal Cancer Patients Who Had Experienced An Oxaliplatin-Related Hypersensitivity Reaction.
S. Horasawa1, A. Kaneko1, D. Kotani2, S. Nakashima1, H. Bando1, T. Yoshino1; 1JP, 2Chiba/JP

K. Suzuki1, S. Yuki2, S. Nakano1, Y. Kawamoto1, H. Nakatsumi1, K. Hatanaka2, T. Ando1, K. Furukawa1, A. Ishiguro1, T. Ohta1, K. Eto1, J. Nakajima1, M. Nakamura1, S. Sogabe1, K. Kato1, M. Tateyama1, S. Katō1, M. Sekiguchi1, Y. Sakata3, Y. Komatsu2; 1JP, 2Hokkaido/JP, 3Aomori/JP

103P - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of cases of prior regorafenib.

104P - Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer.
105P - A China-Manufactured Bevacizumab Biosimilar, HLX04, Matches Avastin® Sourced from China, USA and European Union

106P - Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer

107P - Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): phase Ib results

108P - A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy (Cetux-chemo) in patients (pts) with metastatic colorectal cancer (mCRC) who were previously treated with Cetux-chemo
C.S. Ho, A. Cheng, L. Li, W. Ho, E. Hui, K.F. To, J. Tong, B. Ma; HK

109P - Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study
K.-H. Yeh1, T.-S. Yang1, T.-C. Hsu1, W.T.-L. Chen1, H.-H. Chen1, H.-W. Teng1, B.-W. Lin1, F.-C. Kuan1, F.-F. Chiang1, C.-W. Duann1, Y.-S. Li1, S. Fiala-Buskies2, M. Ducreux3, J.-Y. Wang1; 1TW, 2DE, 3FR

110P - HGCSG1401 : A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction.
A. Ishiguro1, S. Yuki2, S. Nakano1, Y. Kawamoto1, K. Sawada1, Y. Tsuji2, T. Honda1, T. Miyagishima1, S. Yoshida1, K. Hatanaka2, T. Sasaki1, O. Muto1, H. Ohnuma1, S. Kato1, A. Sato1, M. Abe1, K. Kato1, T. Amano2, Y. Sakata3, Y. Komatsu2; 1JP, 2Hokkaido/JP, 3Aomori/JP

111P - TAS-102 Followed by Regorafenib or the Reverse Sequence in Advanced Colorectal Cancer
Y. NAKATANI1, S. Ueda1, Y. Tsuboguchi1, Y. Yoshii1, K. Akiyoshi1, A. Tsuya1, S. Okazaki2, S. Tokunaga1, H. Daga1; 1JP, 2Fushimi-ku/JP
18:00 - 18:00  **112P - Efficacy of regorafenib in metastatic colorectal cancer: a multi-institutional retrospective study**  
M.S. Bazarbashi1, M. Elshenawy2, M. Kandi1, M. Zahir1, A. Shaheen1, A. Gad3, O. Alshaer1, A. Alzahrani1, A. Eldali1, A. Aljubran1; 1SA, 2Menoufia Governorate/EG, 3EG

18:00 - 18:00  **113P - Real world experience with Regorafenib in dose escalation schedule in metastatic colorectal cancer in Indian patients**  
A. Rauthan1, P. Patil1, S.P. Somashekhar1, S. Zaveri2; 1IN, 2Karnataka/IN

18:00 - 18:00  **114P - Role of consolidative radiation therapy after surgery in patients with stage IV rectal cancer**  
T. Mehmood, PK

18:00 - 18:00  **115P - HGCSG1301 : A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment.**  
M. Dazai1, S. Yuki1, K. Sawada2, T. Muranaka1, Y. Kawamoto2, H. Nakatsumi2, S. Nakano2, A. Ishiguro2, M. Tateyama2, A. Sato2, Y. Kobayashi1, M. Nakamura2, H. Okuda2, Y. Takahashi1, K. Eto2, S. Muto2, K. Hatanaka1, T. Amano1, Y. Sakata3, Y. Komatsu1; 1Hokkaido/JP, 2JP, 3Aomori/JP

18:00 - 18:00  **116P - Retrospective Analysis of Outcome in GIST patients on Imatinib in Sarawak General Hospital: A Single Institution Experience**  
Y.Y. Sum, U. Nagaswara, S.K. Kho, C.J. Lim, Y.-Y. Junie Khoo; MY

18:00 - 18:00  **117P - Immunoscore feasibility study in routine postsurgical pathologic review for early-stage colon cancer (CC) cases risk-assessment**  
K. Belaloui1, E. Malifarge1, J. Bohm2, C. Bossard1, R. Dienstmann3, S. Garcia4, C. Geppert5, I. Gogenur6, A. Hartmann5, D. Hatzibougias7, S. Landolfi3, M. Mishaeli8, D. Paez3, P. Patel9, M. Rodriguez-Justo10, J. Szafranska-3, M. van den Eynde11, E. Zavadova12, S. Turcan1, F. Hermitte1; 1FR, 2FI, 3ES, 4CEDEX 20/FR, 5DE, 6DK, 7GR, 8IL, 9IN, 10GB, 11BE, 12CZ

18:00 - 18:00  **118P - The Impact of Universal Immunohistochemistry on Lynch Syndrome Diagnosis in an Australian Colorectal Cancer Cohort**  
Z. Loh1, D. Williams2, L. Salmon2, E. Dow2, T. John2; 1AU, 2VIC/AU

18:00 - 18:00  **119P - Poor-prognosis Locally Advanced Rectal Cancer is Defined by a Molecularly Distinct Subtype**  
J. Zhang, L. Shen, Y. Wang, Y. Deng, L. Yang, J. Wan, Z. Zhang; CN

18:00 - 18:00  **120P - Comparison of incidence and survival outcomes in mucinous and signet-ring cell colorectal cancers with classical adenocarcinoma: A SEER analysis**  
T. Mehmood, PK
18:00 - 18:00 121P - Prognosis of Three Histological Subtypes of Colorectal Adenocarcinoma: A Retrospective Analysis of 8005 Chinese Patients
C. Li, H. Zheng, D. Huang, S. Cai, J. Zhu; CN

18:00 - 18:00 122P - Impact of tumor regression grade as a major prognostic factor in pathological stage II and III rectal cancer after neoadjuvant chemoradiotherapy
J.-S. Kim¹, C. Song², S.-B. Kang², H.S. Lee², K.-W. Lee²; ¹Gyeonggi-do/KR, ²KR

18:00 - 18:00 123P - Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer
Y. Li, J. Peng, D. Huang, X. Ma, S. Cai; CN

18:00 - 18:00 124P - Targeted sequencing of germline colorectal cancer predisposition genes in young Asians
J. Chiang, M.R. Toh, J. Ngeow; SG

18:00 - 18:00 125P - A SEER analysis of increasing disparities in age-related cause specific survival (CSS) among patients with colorectal cancer
T. Mehmood, PK

18:00 - 18:00 126P - STING, an immune biomarker for colorectal cancer
H. Chon, D. Kim, C. Kim; KR

18:00 - 18:00 127P - A model based on a new inflammation-nutrition score and TNM stage for predicting overall survival of patients with colorectal cancer

18:00 - 18:00 129P - Prevalence of Vitamin D deficiency in Chinese Patients with Early Stage Colorectal Cancer
D. Ng, R. Tan, R. Sultana, M. Ang, W. Lim, D. Chong, C. Cwl, S.-L. Koo, S. Seet, Z. Tan, I. Tan; SG

18:00 - 18:00 130P - Liquid Biopsy has a potential to predict the colorectal cancer patients with destiny for recurrence after curative surgery
T. Toshima¹, A. Nyuya¹, U. Umeda¹, K. Yasui¹, K. Yoshida¹, T. Fujiwara¹, A. Goel², T. Nagasaka¹; ¹JP, ²US

18:00 - 18:00 131P - Novel drug discovery for cancer invasion and metastasis

18:00 - 18:00 133P - Molecular characterization of cancer associated fibroblasts in colorectal cancer
T. Aizawa¹, H. Karasawa¹, H. Suzuki¹, A. Yamamura¹, S. Ohnuma¹, T. Kamei¹, T. Naitoh¹, M. Unno²; ¹JP, ²Miyagi/JP
18:00 - 18:00 134P - A retrospective analysis of the association between perioperative carcinoembryonic antigen level and prognosis in stage III colorectal cancer

R. Kozuki<sup>1</sup>, E. Shinozaki<sup>1</sup>, H. Osumi<sup>1</sup>, T. Wakatsuki<sup>1</sup>, M. Suenaga<sup>1</sup>, T. Ichimura<sup>1</sup>, M. Ogura<sup>1</sup>, T. Suzuki<sup>1</sup>, Y. Ota<sup>1</sup>, I. Nakayama<sup>1</sup>, D. Takahari<sup>2</sup>, K. Chin<sup>1</sup>, T. Nagasaki<sup>1</sup>, T. Akiyoshi<sup>1</sup>, T. Konishi<sup>1</sup>, Y. Fujimoto<sup>1</sup>, S. Nagayama<sup>1</sup>, Y. Fukunaga<sup>1</sup>, M. Ueno<sup>1</sup>, K. Yamaguchi<sup>1</sup>; 1JP, 2Aichi/JP

18:00 - 18:00 135P - Association of preoperative CEA with recurrence in high risk of recurrence groups with Stage 2 and 3 colorectal cancer patients received by CapeOX adjuvant chemotherapy

H. Osawa, JP

18:00 - 18:00 137P - Prognostic value of staging FDG PET/CT in patients with metastatic colorectal cancer

E.K. Choi, J.K. Oh, Y.-A. Chung; KR

18:00 - 18:00 138P - Natural killer NKG2A and NKG2D serum levels in patients with colorectal cancer

G. Refaat, A. Mohamed, W. Zaki, M. Adel, M. Amin, M. Deeb, M. Rushdy, N. Safwat; EG

18:00 - 18:00 139P - Prognostic value of high EZH2 expression in patients with colorectal cancer in East Azerbaijan, Iran

Z. Sanaat<sup>1</sup>, R. Dolatkhah<sup>2</sup>, N. Gholami<sup>2</sup>; 1East Azarbaijan/IR, 2IR

18:00 - 18:00 140P - DCLK1 as part of EMT feedback-loop promotes colorectal cancer cell proliferation, invasion, and 5-Fu resistance

Y. Ge<sup>1</sup>, N. Weygant<sup>2</sup>, D. Qu<sup>2</sup>, C.W. Houchen<sup>3</sup>; 1CN, 2OK/US, 3AL/US

18:00 - 18:00 141P - Tumor-Associated Carbohydrate Antigens – Tn Antigen Expression and Contribution in Human Colorectal Cancer

Y. Jiang, T. Wen; CN

18:00 - 18:00 142P - Biological characteristics predict outcome of rectal cancer patients: Data from tertiary care hospital in a low economic country

A. zaki, S. Hirani, S. Sawani, S. Sarwar, M. Moosajee; PK

18:00 - 18:00 143P - The role of molecular biomarker CDKN-2A in early diagnosis of colorectal cancer

Y. Ten, M. Tiilashaykhov, S. Abdujapparov, H. Islamov, Y. Ziyaev; UZ

18:00 - 18:00 144P - The Impact of Bone Fracture on Prognosis of Colorectal Cancer Patients Receiving Chemotherapy.

Y. Sakai, T. Sone, T. Murai, K. Itaya, Y. Ono, M. Nakamura; JP

18:00 - 18:00 145P - pregnancy had no significant impact on young colorectal cancer patients

J. Zhu, J. Wang; CN
18:00 - 18:00  **146TiP - A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer**
T. Yoshino¹, S. Siena², R. Dalal³, Y. Okuda¹, E. Yamamoto¹, A. Grothey⁴; ¹JP, ²IT, ³US, ⁴TN/US

18:00 - 18:00  **147TiP - Impact of the Immunoscore® assay on adjuvant chemotherapy decision making in patients with resected stage II-III colon cancer: A prospective, multicenter study (PROSCORE)**
D. Malka, C. Mollevi, F. Hermitte, A. Catteau, N. LACHAUX, C. Jouffroy; FR

18:00 - 18:00  **YO8 - Delayed perforation after stent placement for sigmoid colon cancer obstruction**
S. Fukai, K. Mizokami; JP

18:00 - 18:00  **YO9 - Durable response to cetuximab plus FOXFOX in metastatic unresectable sigmoid colon cancer**
D. Ratanapichayachai, TH

18:00 - 18:00  **YO10 - Rectal Adenocarcinoma and Ileocecal Tuberculosis: a simple coincidence or a pathologic co-existence?**
J.M.I. Lomanta, C.D. Uy, J. Ignacio, R. Berba; PH

18:00 - 18:00  **Gastrointestinal tumours, non-colorectal**

18:00 - 18:00  **156P - TCOG T1308 Study: The Final Results of a Phase II Trial of modified Gemcitabine plus S-1 combination as the First-line Treatment in Patients with Advanced Biliary Tract Cancer**
N.-J. Chiang¹, L.-T. Chen¹, J.-S. Chen¹, S.-H. Yang¹, C. Hsu¹, Y.-S. Shan¹, C.-J. Yen², M.-H. Chen¹, H.-H. Tsou¹; ¹TW, ²CN

18:00 - 18:00  **157P - Epidemiological parameters and survival outcome of Gall bladder cancer: An North West India based institution study**
S. Narayan¹, P. Pareek²; ¹Rajasthan/IN, ²IN

18:00 - 18:00  **158P - Impact on gemcitabine plus cisplatin in unresectable hilar cholangiocarcinoma patients according to effective bile drainage**

18:00 - 18:00  **159P - Clinical prognostic factors and treatment outcomes for survival of patients with cholangiocarcinoma**
C. Charonponsuntorn, P. Piyasatit, P. Chonmaitree, P. Muangnoi, D. Muntham; TH

18:00 - 18:00  **160P - Common Chromosomal Abnormalities in Gastric Cancer Cell Lines and Ascetic Fluids of Metastatic Gastric Cancer Patients**
18:00 - 18:00 161P - Efficacy and safety of modified ECF regimen as first-line chemotherapy in metastatic gastric adenocarcinoma: A phase II study

18:00 - 18:00 162P - A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
K.-W. Lee1, I.S. Choi2, J.H. Kim1; 1Gyeonggi-do/KR, 2KR

18:00 - 18:00 163P - mFLOT versus EOX in first line treatment of metastatic carcinoma of stomach
V. Srinivasalu1, N. Subramaniam1, W. Jose2, A. Philip3, K. Pavithran2; 1IN, 2Kerala/IN, 3Tamil Nadu/IN

18:00 - 18:00 164P - Gastric Adenocarcinoma Incidence And Mortality Trends In Asian-American Population
M. Gad, A. Saad, M. Al-Husseini; EG

18:00 - 18:00 165P - Prognostic Significance of CT-determined Sarcopenia in Patients with Advanced Gastric Cancer Treated with Chemotherapy

18:00 - 18:00 166P - Assessment of molecular classification of gastric cancer by immunohistochemistry and in situ hybridization: a validation study in the Chinese population
Y. Sun, W. Yu, W. Guan, M. Qiao, L. Zheng, R. Jiang, R. Wang, L. Wang; CN

18:00 - 18:00 167P - Pattern of gastric cancer in young(GCY) : A retrospective study from a tertiary cancer care centre in Indian subcontinent.
S. Kumar, K. Gupta, T. Murali, K. Dharma, A. Anand, M. Bhandare, V. Chaudhary, S. Shrikhande; IN

18:00 - 18:00 168P - Optimal time interval between surgery and adjuvant chemotherapy of gastric cancer

18:00 - 18:00 169P - Apatinib reverses resistance of paclitaxel-containing regimens in advanced gastric cancer: a phase II study
R. Lin, N. Fan, H. Li, J. Liu, S. Zhao, J. Yu; CN
170P - Early Results of Pegvorhyaluronidase Alfa (PEGPH20; PVHA) + Pembrolizumab Therapy in Patients (Pts) with Relapsed/Refractory Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma
R.D. Harvey¹, A. Murphy², E. Kim³, M. Tejani⁴, W. Wu³, E. Pham⁵, M. Muhsin⁵; ¹AL/US, ²MD/US, ³CA/US, ⁴NY/US, ⁵US

171P - A novel method of measuring exosomal HER2 to assist in selecting advanced gastric cancer patients benefiting from anti-HER2 therapy
Q. Li¹, X. Xu¹, Y. Yu¹, W. Li¹, L. Liang¹, J. Song¹, X. Zhao¹, S. Cai¹, T. Liu²; ¹CN, ²Changning/CN

172P - CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving 2nd-line chemotherapy

173P - How can we predict the possibility of advanced gastric cancer patients to receive third-line chemotherapy in the real-world setting?
M. Ueno, A. Doi, H. Mouri, M. Mizuno; JP

174P - EMT markers gene expression in BPIFB2 overexpressed gastric cancer cell lines
Z. Karim, N.A. Zulkifli, S.H. Sheikh Abdul Khalil, K. Abd Khalil, M. Musa; MY

175P - Overall Survival Results From a Phase 3 Trial of Trifluridine/Tipiracil (FTD/TPI) vs Placebo in Patients (Pts) with Metastatic Gastric Cancer Refractory to Standard Therapies (TAGS)
K. Shitara¹, J. Tabernerò², M. Dvorkin³, W. Mansoor⁴, H.-T. Arkenau⁴, A. Prokharau⁵, M. Alsina², M. Ghidini⁶, C. Faustino⁷, V. Gorbunova³, E. Zhavrid⁵, K. Nishikawa¹, A. Hosokawa¹, D. Ganea³, S. Yalçın⁹, K. Fujitani¹, G. Beretta⁶, R. Winkler¹⁰, T. Doi¹, D. Ilson¹⁰; ¹JP, ²ES, ³RU, ⁴GB, ⁵BY, ⁶IT, ⁷PT, ⁸RO, ⁹TR, ¹⁰AL/US

176P - Superior antitumor efficacy of interferon incorporated hydrogels combined with CIK and radiation against gastric cancer
Q. Liu, D. Zhang, H. Qian, B. Liu; CN

177P - Long-term results of conversion therapy for initially unresectable gastric cancer: analysis of 122 patients at the National Cancer Center in China
T. Wang, N. Wang, H. Ren, H. Zhou, A. Zhou, J. Jin, Y. Chen, D. Zhao; CN

178P - FOXO3 inhibits human gastric adenocarcinoma (AGS) cell growth by promoting autophagy in an acidic microenvironment
Y. Gao, CN

179P - Efficacy and Safety of Regorafenib after Progression on Sorafenib in Korean Patients with Advanced Hepatocellular Carcinoma (HCC)
180P - Prognostic Factors affecting the survival of hepatocellular carcinoma patients undergoing different surgical techniques
S. Ahmed, M. Morsi, I. Uthman; EG

181P - GNMT negatively regulates MAPK Pathway and suppresses the growth and metastasis of Hepatocellular cancer cells
S. Jiang, F. Jingyuan; CN

182P - Lenvatinib acts as the salvage therapy for advanced hepatocellular carcinoma
M.-C. Hsieh, Y.-L. Su, Y.-Y. Chen, C.-T. Liu, Y.-H. Chen, T.-J. Chiu, S.-N. Pei, C.-C. Wu, K.-M. Rau; TW

183P - Response to Multi-Targeted Kinase Inhibitor (MKI) after Immune Checkpoint Inhibitor (ICI) in Patients with Hepatocellular Carcinoma (HCC)
S. Chng, S. Tan, J. Lee, S.P. Choo; SG

184P - Continued Value of the Serum Alpha-Fetoprotein in Surveilling At-Risk Populations for Hepatocellular Carcinoma

185P - Role of Tie2, CD14, angiopoietin as angiogenetic markers in hepatocellular carcinoma complicating hepatitis C virus infection in Egyptian patients
E.-Z. Meghezel, H. Abdelhfez Ahmed, A. Askar, E.E. Hassan, A. Elyamany; EG

186P - Phase 2 trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients

187P - Outcome of induction chemotherapy consisting of docetaxel, cisplatin, and S-1 (DCS) followed by esophagectomy for cT4 esophageal cancer in comparison with chemoradiotherapy
H. Shimoji, T. Nishimaki, H. Karimata, Y. Nakamura; JP

188P - Outcome of Small Cell Carcinoma of Esophagus: An Institutional Experience from North-East India
P. Roy1, B. Saikia2, M. Hazarika2, C. Bhuyan2, G. Kumar2, R. Mishra2, C.W. Nyuthe2; 1Assam/IN, 2IN
Efficacy of palliative chemotherapy (CTx) by lines of treatment in patients (pts) with recurrent/metastatic esophageal squamous cell cancer (SCC): Retrospective analysis of 103 patients in single center


Metastatic to negative lymph node ratio - can it used as a prognostic indicator in squamous cell carcinoma esophagus

G. M.s, IN

Nomogram to predict cancer-specific survival in patients with pancreatic acinar cell carcinoma: A competing risk analysis

C. He, S. Li; CN

Use of FOLFIRINOX chemotherapy in an Australasian population of pancreatic cancer

A. Jalali1, M. Lee2, C. Semira3, S. Banks3, H.-L. Wong1, S. Ananda1, L. Lipton1, J. Shapiro1, P. Cooram1, K. Clarke4, M. Burge5, R. Wong1, J. Shapiro3, S.-A. McLachlan3, M. Harris1, D. Croagh3, N. Tebbutt1, P. Gibbs1, B. Lee1; 1VIC/AU, 2ACT/AU, 3AU, 4NZ, 5QLD/AU

Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

H.N.N. Ip1, I. Hwang2, J. Kang2, K.-P. Kim2, J.H. Jeong2, H.-M. Chang2, B.-Y. Ryoo2, C. Yoo2; 1HK, 2KR

Runx1 enhancer element marks stem/progenitor cells in pancreas and can be an origin of cancer

H. Sato1, A. Yamamura1, J. Matsuo2, Z. Hossain2, M. Osato2, T. Naitoh1, T. Kamei1, M. Unno3, Y. Ito2; 1JP, 2SG, 3Miyagi/JP

Symptoms at diagnosis of (metastatic) pancreatic adenocarcinoma (mPAC) in routine practice and frequency variation across Europe

A. Carrato Mena1, D. Melisi2, B. Westphalen3, Å. Mellbring4, J. Taieb5, G. Prager6, T. Macarulla Mercadé1, N. D’esquermes5, A. Ferreras5, P. de Jong7; 1ES, 2IT, 3DE, 4SE, 5FR, 6AT, 7CH

HGCSG1403 : Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer.

A. Yoshikawa1, Y. Kawamoto1, S. Yuki2, S. Nakano1, K. Sawada1, T. Muranaka2, H. Nakatsumi1, K. Harada1, Y. Kobayashi2, T. Miyagishima1, T. Saiki1, A. Ishiguro1, R. Saito1, N. Ehira1, I. Iwanaga1, K. Hatanaka2, N. Abe1, N. Sakamoto1, Y. Sakata3, Y. Komatsu2; 1JP, 2Hokkaido/JP, 3Aomori/JP

Expression of p16 and KRAS in periampullary cancers

J. swain, M.T. Tewari; IN
18:00 - 18:00 199P - Incidence, risk factors, and outcomes of arterial thromboembolism in patients with pancreatic cancer following palliative chemotherapy

18:00 - 18:00 200P - Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: further subgroup analyses of the pivotal NAPOLI-1 study
L.-T. Chen¹, T. Macarulla Mercadé², K.-H. Lee³, G. Lakatos⁴, A. Wang-Gillam⁵, B. Mirakhur⁶, F. de Jong⁷; ¹TW, ²ES, ³KR, ⁴HU, ⁵MO/US, ⁶US, ⁷CH

18:00 - 18:00 201P - Three-dimensional remnant pancreatic volumetry as an indicator of poor prognosis in pancreatic cancer patients after pancreatoduodenectomy
R. Miyamoto, N. Sano, M. Maeda, S. Inagawa; JP

18:00 - 18:00 202P - GLRLM feature by using CT texture analysis is prognostic factor, Evaluation of pancreatic cancer heterogeneity
H.S. Kim, J.S. Park, Y.J. Kim, K.G. Kim; KR

18:00 - 18:00 204P - Prognostic impact of progression type by RECIST criteria in patients with metastatic pancreatic cancer who received 1st line gemcitabine based chemotherapy
J. Lee, M.A. Lee, I.-H. Kim; KR

18:00 - 18:00 205P - Trends in the Incidence, Prevalence, and Survival Outcomes of Appendiceal Adenocarcinoma
W. Xiang, G. Cai; CN

18:00 - 18:00 206P - Incidence of catheter-related thrombosis in patients with long-term indwelling central venous catheter who received chemotherapies for unresectable advanced digestive cancers

18:00 - 18:00 207TiP - A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr Virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies
B. Liu¹, J. Yan¹, S. Su¹, J. Shao¹, Y. Zhao¹, Q. Xu¹, Y. Yang¹, Z. Zou¹, X. Huang¹, J. Wei²; ¹CN, ²Jiangsu Province/CN

18:00 - 18:00 208TiP - A randomized, phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
K. Shitara¹, Y.-J. Bang², D. Sakai³, H. Yasui³, Y. Kawaguchi³, M. Sugihara³, K. Saito³, R. Dalal⁴, K. Yamaguchi⁵; ¹Chiba/JP, ²KR, ³JP, ⁴US
18:00 - 18:00  **209TiP - CA209-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Curative Resection or Ablation**


18:00 - 18:00  **210TiP - IMbrave150: a randomised Phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma**


18:00 - 18:00  **211TiP - HALO 110-101: Phase 1b Study of PEGPH20 in Combination with Cisplatin + Gemcitabine (PEGCISGEM) or Atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in Patients with Locally Advanced/Metastatic Cholangiocarcinoma and Gallbladder Cancer**

D.-Y. Oh¹, J.-O. Park¹, C. Charoentum², S. Stein³, M. Noel⁴, V. Chung⁵, W. Wu⁵, R. Alton⁵, M. Muhsin⁶, M. Javle⁷, G. Abou-Alfa⁴, M. Borad⁸; ¹KP, ²TH, ³CT/US, ⁴NY/US, ⁵CA/US, ⁶US, ⁷TX/US, ⁸AZ/US

18:00 - 18:00  **YO11 - Hepatocellular carcinoma responding to sequential radioembolization and external radiotherapy: A successful salvage?**

A. Ahmed, QA

18:00 - 18:00  **YO12 - Solid Pseudopapillary Tumor of Pancreas: A Case Report**

S. m, G. Ushashree, N. Rao, R. Reddy; IN

18:00 - 18:00  **YO13 - Synchronous adenocarcinoma and gastrointestinal stromal tumors in the stomach**

H. Ubaydullaeva, UZ

18:00 - 18:00  **YO14 - Gastrointestinal perforation caused from colonofiberscopy to lung adenocarcinoma with metastasises small intestine ; a case report**

N. Haruta, Y. Haruta, M. Matsu, K. Murase; JP

18:00 - 18:00  **YO15 - A case of Obstructive Jaundice in Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy**

A. Giselvania, A. Munandar, G.B. Prajogi, S.M. Sekarutami, S. Gondhowiardjo; ID

18:00 - 18:00  **Genitourinary tumours, prostate**
215P - Comparison between robot-assisted radical prostatectomy and minimum incision endoscopic radical prostatectomy for high-risk prostate cancer following neoadjuvant therapy: A propensity score-matched analysis

216P - The impact of different treatment modalities on toxicity and quality of life for prostate cancer - a real-world study based on WeChat in China
X. Qi, H. Li, S. Gao; CN

217P - HoxB13 expression in prostate cancer: clinicopathologic characteristics and role as potential diagnostic marker

218P - Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-stage localized prostate cancer: acute toxicity results from a prospective randomized phase II study
D. Poon¹, D. Lam¹, K. Wong¹, F. Mok², F. Mo¹, C.M. Chu¹, A.C.F. Ng¹, J. Suen¹, A. Chan¹; ¹HK, ²Kowloon/HK

219P - The linear-quadratic (LQ) model is inappropriate for high doses per fraction owing to α/β ratio is not a constant: evidence deduced from radiotherapy outcomes of 16367 prostate cancer patients.
M. Cui, S. Gao; CN

220P - Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)
A. Anton¹, S. Wong², P. Parente², A. Azad², J. Shapiro¹, A. Weickhardt², J. Torres², F. Parnis³, J. Goh⁴, C. Semira¹, P. Gibbs², B. Tran¹, C. Pezaro²; ¹AU, ²VIC/AU, ³SA/AU, ⁴QLD/AU

221P - Prognostic impact of pT3a subclassification based on extent of extraprostatic extension after robot-assisted radical prostatectomy.

222P - Immunotherapy with dendritic cells derived from bone marrow hematopoietic stems cells inhibited tumor growth on a TRAMP-C1 syngeneic mouse model of prostate cancer
Y. Kim, B.-M. Kim, C.-S. Kim, H. Kim, S.Y. Choi, H. Lee; KR

223P - Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy.
A. Anton¹, Z. Ballok¹, P. Bowden², T. Costello³, L. Harewood³, N. Corcoran³, P. Dundee³, J. Peters³, N. Lawrence-Suk³, A. Troy³, D. Webb³, Y. Chan³, A. See³, S. Siva³, D. Murphy³, M. Hofman³, B. Tran¹; ¹AU, ²ACT/AU, ³VIC/AU
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 - 18:00</td>
<td>224P - A new novel gene ABCC5 promotes castration-resistant prostate cancer progression through ERK carcinoenic pathway</td>
<td>G. Ji, CN</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>225P - Docetaxel versus Abiraterone in Newly Diagnosed Metastatic Prostate Cancer: Study from Tertiary Care Cancer Centre in a Developing Country</td>
<td>S. Hussain, G. Gautam, P. Ahluwalia, A. Punnakal, H. Chaturvedi, A. Gupta; IN</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>226P - Aldo-keto-reductase 1C3 expression in prostate cancer</td>
<td>Y. Hashimoto, A. Imai, H. Yamamoto, S. Hatakeyama, T. Yoneyama, C. Ohyama; JP</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>227P - LOCALISED CARCINOMA PROSTATE: Intensity Modulated Radiotherapy (IMRT) Followed By Stereotactic Body Radiotherapy (SBRT) Boost: A Feasibility Study For Acute Toxicity.</td>
<td>G. Deepthi, N. Kumar, S. Kumar, B. Yadav, P. Gupta; IN</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>228P - Upfront Chemotherapy for High Volume HSPC, Single Institute Experience of Southern Taiwan</td>
<td>C.-M. Tsai, J.-T. Lin, C.-C. Yu, T. Wu, I.-H. Cheng, M.-X. He; TW</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>229P - Predictability of intra-fractional prostate motion</td>
<td>K. Perumal, M. Potharaju; IN</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>230P - Utility of Gallium-68 PSMA PET/CT Scan for Staging and Treatment of Prostate Cancer in Contemporary Era: Study from Tertiary Care Cancer Centre in a Developing Country</td>
<td>A. Gupta, S. Hussain, P. Ahluwalia, G. Gautam, A. Punnakal, H. Chaturvedi, A. Rajput, J. Bal, P. Dougall; IN</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>Genitourinary tumours, non-prostate</td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>234P - Quantitative proteomic analysis identifies AHNAK as a novel candidate biomarker for bladder urothelial carcinoma diagnosis</td>
<td>C. hyun, M.S. Park; KR</td>
</tr>
<tr>
<td>18:00 - 18:00</td>
<td>235P - Comparison of Cisplatin versus Carboplatin Chemotherapy for Metastatic Urothelial Carcinoma in Patients with Stage 3 Chronic Kidney Disease</td>
<td>C.-C. Wu, K.-M. Rau, M.-C. Hsieh, Y.-L. Su; TW</td>
</tr>
</tbody>
</table>
18:00 - 18:00  236P - The relationship between preoperative stage 3B chronic kidney disease and post-surgical oncological outcomes in patients with urothelial carcinoma

18:00 - 18:00  237P - High expression of sushi domain containing 2 (SUSD2) promote cell proliferation in bladder cancer and was associated poor survival outcome.
C. Wang, TW

18:00 - 18:00  238P - Role of Post Lasix FDG PETCT in Recurrent Carcinoma Bladder
S. Malapure, R. Kumar, P. Sharma; IN

18:00 - 18:00  239P - Correlation of DNA damage and urinary cotinine levels in cases of carcinoma urinary bladder.
T. Singh, S. Gupta, P. Garg; IN

18:00 - 18:00  240P - Determine cisplatin or carboplatin in first-line chemotherapy for elderly patients with metastatic urothelial carcinoma: Does age preclude cisplatin eligibility?
S.Y. Huang, Y.-L. Su, M.-C. Hsieh, K.-M. Rau; TW

18:00 - 18:00  241P - Does neoadjuvant chemotherapy promote chemoresistance after recurrence in patients with muscle-invasive bladder cancer?

18:00 - 18:00  242P - A Novel Cost-effective Method for Diagnosis of Bladder Cancer by Detecting ErbB3 Expression in Urine
X. Chen, S. Wang, C. Liu, J. Chen, D. Wang, M. Huang, J. Song, S. Cai, S. Qiu; CN

18:00 - 18:00  243P - Node-positive bladder cancer after neoadjuvant chemotherapy followed by radical cystectomy: a single-center retrospective study

18:00 - 18:00  244P - Lipid cell change in urothelial carcinoma - Signs of tumor aggression and the worst prognosis among the variants -
T. Hayashi, G. Kimura, Y. Kondo; JP

18:00 - 18:00  245P - comparison of partial nephrectomy and percutaneous radiofrequency ablation for small renal mass in the manner of PADUA classification
W.-T. Kuo, TW

18:00 - 18:00  246P - Patient characteristics, patterns of care and survival outcome in patients with Adult testicular granulosa cell tumor: an individual patient data meta-analysis
S. Thambi\textsuperscript{1}, R. Benson\textsuperscript{2}, L. Haridas\textsuperscript{1}; \textsuperscript{1}IN, \textsuperscript{2}Delhi/IN
18:00 - 18:00 247P - Clinicopathological and survival analysis of endometrial carcinoma: a single center experience in Pakistan
Z. Samoon, S. Ahmed, S. Jehangir, S. Rizvi, S. Sawani; PK

18:00 - 18:00 249P - The gap of frailty value from a community-dwelling population predict oncological outcomes in patients with urological cancers
S. Hatakeyama, S. Konishi, K. Okita, O. Soma, T. Matsumoto, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP

18:00 - 18:20 YO16 - Urothelial carcinoma of the kidney in a patient with ovarian and breast cancer
F.V. Que, PH

18:00 - 18:20 YO17 - Induction Chemoradiation Therapy in Recurrent Locally Advanced Urachal Cancer
T. Dajsakdipon, S. Worawichawong, C. Leenanupunth, P. Phichai Chansriwong; TH

18:20 - 18:20 Gynaecological cancers
A.M. Poveda Velasco¹, J.-W. Kim², E. Pujade-Lauraine³, H.Y.-S. Ngan⁴, C. Scott⁵; ⁱES, ²KR, ³CEDEX 4/France, ⁴HK, ⁵AU

18:20 - 18:20 257P - Correlation between Knowledge and Attitudes of Female High School Students Regarding Cervical Cancer in Denpasar, Bali
R. Martianus, R. Putri, A. Satyarsa, Y. Brahmantya, A. Abdulhadi; ID

18:20 - 18:20 258P - Screening Program for cervical cancer among rural women by Visual Inspection with Acetic Acid (VIA): A Camp approach in Eastern India
I. Mandal, J. Basak, A. Mukhopadhyay, C. Bose; IN

18:20 - 18:20 259P - Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomized studies
Z. Olimova, UZ

18:20 - 18:20 260P - Neoadjuvant intraarterial chemotherapy and chemoembolization in locally advanced cervix cancer
O. Akhmedov, N. Zakhirova, N. Umarova; UZ

18:20 - 18:20 261P - Concurrent Chemoradiation with Nano- Paclitaxel and Carboplatin in Locally Advanced Cervical cancer - A Study at Quaternary Care Medical Center
P. Eswaran¹, S. Kalyan², J. Crystal²; ¹Tamil Nadu/IN, ²IN

18:20 - 18:20 262P - Is Bone Marrow sparing Intensity modulated radiotherapy better than 3-Dimensional Conformal radiotherapy in reducing haematological toxicities during pelvic irradiation in locally advanced carcinoma cervix?: A prospective study.
A. Elangovan, A. Bahl, F. Patel, C.B. DRACHAM, B. Rai, G. Trivedi; IN
263P - Pelvic plastic reconstruction results after small pelvis exenteration
M. Tillashaykhov, N. Zakhirova, O. Ahmedov, Y. Ten, S. Djaniklich; UZ

264P - Development of the surgery method of pelvic floor reconstruction in locally advanced cervical cancer after exenteration
N. Zakhirova, M. Tillashaykhov, O. Akhmedov, S. Djaniklich, Y. Ten; UZ

265P - Life after cervical cancer: Bowel dysfunction, Urinary dysfunction and quality of life in long-term survivors of carcinoma uterine cervix among Indian women.
N. Sethi, A. Shankar, J. Patil, K. Mandrelle, A. Luther; IN

266P - Efficacy of Multimodality Treatment in Survival Patterns among Patients with Endometrial Carcinoma Stage III
R. Elemam, I. Uthman, A. Yahya, N. Mohamed, A. Shaltout; EG

267P - HPV E6/E7 oncoprotein promotes cervical cancer by promoting miR-466 expression via P53 pathway
Y. Shen, Q.-X. Xu; CN

269P - miRNA-96 might serve as potential biomarkers for cervical cancer
J.-M. Gong, CN

271P - Prevalence of BRCA and VUS Mutations in Patients with Ovarian Cancer Treated at Oncosalud - AUNA
C. Flores, P. Carrion Calderon; PE

272P - Clinical background and outcomes of risk-reducing salpingooopherectomy for patients with hereditary breast and ovarian cancer in Japan
H. Nomura, M. Sekine, S. Yokoyama, N. Takeshima, M. Arai, S. Nakamura; JP

273P - Olaparib maintenance treatment, the Royal Marsden experience
C. Orbegoso Aguilar, L. Dumas, E. Davies, M. Gore, A. George, S. Banerjee; GB

274P - Real-world experience of olaparib maintenance in high grade serous recurrent ovarian cancer patients with BRCA 1/2 mutation

275P - Efficacy and tolerability of Olaparib in Asian patients with recurrent ovarian, primary peritoneal or fallopian tube carcinoma: the National University Cancer Institute, Singapore experience.

276P - Overexpression of HER3 and the survival of ovarian cancer
18:20 - 18:20 277P - Investigation of the role of transforming growth factor beta in the development and progression of granulosa cell tumours of the ovary
A. Muthukaruppan, S.K. Arora, C. Blenkiron, A. Shelling; NZ

18:20 - 18:20 278P - Predicting CA-125 Status and Ovarian Cancer Survival Using Artificial Neural Networks
M. Osman, EG

18:20 - 18:20 279P - PET/CT in recurrent carcinoma ovary: Contrast enhanced CT (CECT) versus non enhanced low-dose CT (NECT)
A. Vyas, A. Tiwary, A. Aggarwal; IN

18:20 - 18:20 280TiP - GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer
K. Tewari1, I. Vergote2, A. Oaknin3, E. Alvarez1, S. Gaillardon, S. Lheureux5, D. Rischin6, A. Santin7, M. Feng4, M. Mathias8, M. Fury9, I. Lowy8, B. Monk9; 1US, 2BE, 3ES, 4AL/US, 5AB/CA, 6ACT/AU, 7CT/US, 8NY/US, 9AZ/US

18:20 - 18:20 YO18 - Ovotesticular mixed germ cell tumor in a 46,XY/46,XX hermaphrodite: a case report
R. So, I. Orolfo-Real, J.A. Toral, S. Paloyo, E.M. Cutiongco-Dela Paz; PH

18:20 - 18:20 YO19 - Recurrent Intracranial Hemorrhage in a Patient with Metastatic Choriocarcinoma to the Brain Mimicking as Vasculitis
A. Gerodias, E. Esposo, J. Datukan; PH

18:20 - 18:20 Haematological malignancies

18:20 - 18:20 281P - Significance of PARP1 Expression levels in patients with Acute Myeloid Leukemia

P. Simha1, D. Lokanatha1, K. Govind Babu1, L. Jacob1, M. Suresh Babu1, K.N. Lokesh2, A. Rudresha2, L. Rajeev1, S. Smitha1, G. Giril1; 1IN, 2Karnataka/IN

18:20 - 18:20 283P - High Dose Methotrexate in Acute Lymphoblastic Leukemia without monitoring drug levels: Indain Experience
285P - Karyotype Complexity and characterization of childhood acute myeloid leukemia (AML) in Pakistan
Z. Ahmed1, M. Shaiaikh2, T. Moatter2, A. Nasir2; 1Sindh/PK, 2PK

286P - First China-Manufactured Proposed MabThera® Biosimilar Met Primary Efficacy and Safety Endpoints in CD20-Positive Diffuse Large B-Cell Lymphoma

287P - Peripheral blood neutrophil-to-lymphocyte ratio in NK/T-cell lymphoma - prognostic significance and correlation with tumor transcriptomic profiles
T. Khee Ming1, B. Chia1, J.Q. Lim1, L.P. Khoo1, C.L. Cheng1, L. Tan1, J.Y. Chan1, E.Y.L. Poon1, N. Somasundaram1, M. Farid1, T.P.L. Tang1, M. Tao1, D.M.Z. Cheah1, Y. Laurensia1, J.W.L. Pang1, S.J. Kim2, W.S. Kim2, C.K. Ong1, S.T. Lim1, T. Song1; 1SG, 2KR

288P - Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil.
S. Ko, S.-N. Lim, B.S. Sohn; KR

289P - Safety and efficacy of pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma from China
Y. Song1, X. Hong1, H. Huang1, B. Bai1, H. Zhang1, X. Ke1, Y. Shi1, J. Zhu1, G. Lu1, S. Liebscher2, C. Cai1; 1CN, 2DE

290P - Extranodal NK/T Cell Lymphoma- Nasal type: Experience from an Indian regional cancer centre
S. Saldanha1, K. Govind Babu2, D. Lokanatha2, L. Jacob2, M. Suresh Babu2, K.N. Lokesh1, A. Rudresha1, L. Rajeev2, G. Giri2, P. Khandare2; 1Karnataka/IN, 2IN

291P - Clinicopathologic features of breast lymphoma in core needle biopsy
R. Shui, J. Rao, X. Li, W. Yang; CN

292P - Erectile dysfunction among male lymphoma survivors in a developing country
G. Gan, D. Ng, Y. Leong; MY

293P - An Attempt to Predict Double Expresser DLBCL Based on Cell of origin and Proliferative Index (Ki-67): A Prospective Study from India
V. Asati1, C. Premalata1, K. Govind Babu1, K. Lakshmaiah1, D. Lokanath1, L. Jacob1, M. Suresh Babu1, K.N. Lokesh2, A. Rudresha2, L. Rajeev1, S. Smitha1, G. Giri1, D. Koppaka1, T. Chaudhuri1, A. Anand1, R. Chethan1, A. Goyal1, R. Patidar1; 1IN, 2Karnataka/IN
**294P** - A Prospective Study to Determine Survival Outcome to CHOP-based therapy in patients with Double Expresser DLBCL: Single Centre Experience from India

V. Asati1, K. Lakshmaiah1, K. Govind Babu1, D. Lokanath1, L. Jacob1, M. Suresh Babu1, K.N. Lokesh2, L. Rajeev1, A. Rudresha2, S. Smitha1, G. Giri1, D. Koppaka1, A. Anand1, R. Chethan1, T. Chaudhuri1, R. Patidar1, A. Goyal1, C. Premalata1; 1IN, 2Karnataka/IN

**295P** - A Strategy of Stringent Control of Side-effects prevent the incidence of methotrexate related lymphoproliferative disorders in rheumatoid arthritis

Y. URATA, JP

**296P** - Is fusion of a baseline PET really necessary in radiation treatment planning of early stage Lymphomas?? Or will a baseline CT suffices??

M. Muddabhaktuni, B. Yadav, N. Kumar, G. Prakash, B. Mittal, S. Goshal; IN

**297P** - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Patients with early stage classical Hodgkin lymphoma

L. Omar, E. Ali, A. Abd Elbaset; EG

**298P** - The prognostic significance of baseline serum Ferritin in patients with malignant Lymphoma

D. El-Habashy, E. Tawfik, S. Alhassanin, A. El-Desoky, A. Shehata; EG

**299P** - Efficacy of salvage therapy of Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma

S.-N. Lim, S. Ko, B.S. Sohn, S.Y. Oh; KR

**301TiP** - A phase 3 randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia

J. Wang1, J. Li1, A. Tantiworawit2, S. Izuka3, S. Yamada3, J. Hill4, E. Shima Rich5, E. Bahceci4; 1CN, 2TH, 3JP, 4IL/US, 5AL/US

**302TiP** - Safety and Efficacy of Midostaurin in Patients With Newly Diagnosed FLT3-Mutated AML


**YO20** - Dyspnoea on Anti CD 38 directed IgG1k monoclonal Antibody - A Case Report

R. Arora, IN

**YO21** - NK/T Cell Lymphoma, Nasal Type in a Filipino Male

A.T. Gerona, PH
YO22 - Chemotherapy in Bulky Neck Mass DLBCL with Massive Gastrointestinal Bleeding Due to Erosive Gastritis and Myelodysplasia Syndrome: A Case Report
Y. Putra, M. Hardianti; ID

18:20 - 18:20  Head and neck cancer, excluding thyroid

308P - Prophylactic percutaneous endoscopic gastrostomy in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy
T. Dechaphunkul, N. Ngamphaiboon, P. Danchaivijitr, R. Jiratrachu, A. Dechaphunkul; TH

309P - To evaluate Oncological and Quality of life outcomes between Robotic and open neck dissection for oral cavity cancers: A prospective trial.
K. Gupta, S. Dabas; IN

310P - Analgesic efficacy in Head and neck cancer patients using tapentadol vs. tramadol plus paracetamol
R. Narayanasamy, S. Thiagarajan, K. Perumal; IN

311P - Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial.
X. Hua1, L. Chen1, Q. Zhu1, W. Hu1, C. Lin1, Z. Long1, W. Wen1, X. Sun1, Z. Lu1, Q. Chen1, D. Luo1, R. Sun1, H. Mo1, L. Tang1, W. Zhang1, Z. He1, H. Mai1, H. Lin1, L. Guo2; 1CN, 2Guangdong/CN

312P - Weight loss during Radiation Therapy in Patients of Head &
S. Das, D. Lahiri, S. Mandal, P. Biswas; IN

313P - Study of the cellular immunity in children and adolescents with nasopharyngeal cancer
N. Karimova, D. Polatova, A. Ismailova, I. Iskandarova, M. Boboev; UZ

314P - Association of immune-related adverse events and efficacy in Japanese patients with squamous cell carcinoma of the head and neck treated with nivolumab

315P - Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a non-endemic cohort of South India

Last update: 09-11-2018 02:52:09pm
317P - Nasopharyngeal carcinoma in children and adolescent: A 10-year review in Sarawak General Hospital, Malaysia.

318P - Induction chemotherapy with docetaxel plus cisplatin followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:8-year follow-up

319P - Oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in non-distant metastatic stage IV of nasopharyngeal carcinoma
J.-H. Chen; TW

320P - Weekly Docetaxel Concurrent Chemoradiotherapy Versus Cisplatin in Locorregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis
J. Liao; CN

321P - The Efficacy of Induction Chemotherapy in Stage II Nasopharyngeal Carcinoma in IMRT Era
P.-J. Li; CN

322P - Gender differences in risk of developing Nasopharyngeal Cancer (NPC) in one of the highest NPC ethnic in the world.

323P - Strong family history of nasopharyngeal carcinoma (NPC) in Bidayuh, a local native group in Sarawak, Malaysia.
G.G. Yeo, S.P. Beh, C.K. Tan, V. Pei Jye; MY

S. LIU, D. Xie, S. Zhou, C. Xu, Z. Ye, S. Liu, G. Wang, S. Ding, Y. Xia; CN

325P - Comparing different normal tissue complication probability (NTCP) models of radiation-induced temporal lobe injury after intensity-modulated radiation therapy for nasopharyngeal carcinoma
L. Zeng; CN

326P - A curative-intent endoscopic surgery for postradiation nasopharyngeal necrosis in patients with nasopharyngeal carcinoma
X. Zou1, M. Chen2, Y.-P. Liu1, S.-L. Wang1; 1CN, 2Guangdong/CN
18:20 - 18:20  **327P** - Two miRNA signatures for identifying nasopharyngeal carcinoma from head-neck tumors and the normal

W. Wen, CN

18:20 - 18:20  **328P** - Unlocking the potential of saliva-based test to detect HPV-driven oropharyngeal cancer.

K.D. Tang¹, C. Punyadeera²; ¹AU, ²QLD/AU

18:20 - 18:20  **329P** - Function Preservation with Trimodality Therapy in Locally Advanced Oral Tongue Squamous Cell Carcinoma

U. Khaleeq¹, A. Rashid¹, T. Abbas¹, S. Rasheed¹, A. Raza¹, M. Khan¹, H. Mahmood¹, Y. Hameed², R. Hussain¹, A. Jamshed³; ¹PK, ²TN/US, ³Punjab/PK


H. Dhar, S. Thiagarajan; IN

18:20 - 18:20  **331P** - The role of ultrasound and ultrasound guided Fine needle aspiration cytology in detection and management of neck node metastases in clinically N0 patients with carcinoma of upper aero-digestive tract in remote part of underdeveloped country.

M. Gubhaju, A. Bajracharya; NP


N. Paulose, IN

18:20 - 18:20  **333P** - Different treatment response in several head and neck squamous cell carcinoma cell lines possibly reflecting underlying molecular signatures

J.P. Chen, J.-Y. Chang, R.-L. Hong; TW

18:20 - 18:20  **334P** - Surgery versus combined radiotherapy and chemotherapy: survival patterns among patients with laryngeal squamous cell carcinoma stage III and IV

A. Abobkr, A. Shaltout, R. Elghareeb, N. Mohamed, I. Uthman; EG

18:20 - 18:20  **335P** - Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN)

R.R. Ganta, S. Nasaka; Andhra Pradesh/IN

18:20 - 18:20  **336P** - Cys144Arg &&

S. Yadav¹, D. Parmar²; ¹Uttar Pradesh/IN, ²IN

18:20 - 18:20  **338P** - Palliative Chemotherapy (CT) with or without Cetuximab (CTX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): An Indian Retrospective Analysis
339P - Decreased expression of NDRG2 predicts poor clinical outcome in patients with oral squamous cell carcinoma.

340P - Differential approach to the bone tumors of the maxillofacial region according to computed tomography signs
A. Almanova, M. Khodjibekov; UZ

341P - Human Papillomavirus (HPV) associated oral cavity and oropharyngeal cancers: cross-sectional follow-up study in south Asian country, Sri Lanka.
P.K.D.P. Alahakoon, K.A. Perera, W.S. Pannala; LK

342P - Survival predictors of Major Salivary Gland Cancer

343P - Histopathologic diagnosis of tumors in the external auditory canal: Recent 7-year experience from a single center in Daegu, Korea
Y.-H. Kim; KR

344P - Evaluation of oral cancer trends in Pakistan during the period 2010 to 2016.
N. Malkani, A. Mahmood; PK

YO23 - Nivolumab Induced Immune Thrombocytopenia in a patient with Relapsed Carcinoma of Tongue
A. Sreevatsa, M. Kamath; IN

S. m, H. Manchala, S. Kumari; IN

YO25 - Primary Neuroendocrine Tumor of the Maxilla: A Case Report
C.D. Uy, C.C. Esplana, G. Fernando; PH

Melanoma and other skin tumours
C. Robert, FR

348P - Interim analysis of prospective observational study on the efficacy of nivolumab for Japanese advanced melanoma patients (CREATIVE study)
349P - Dynamics of clinical biomarkers as predictors of immunotherapy (IT) benefit in metastatic melanoma (MM) patients (pts) treated in reference institution.

350P - Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era

351P - Clinicopathological and prognostic significance of Programmed death ligand 1 expression in Korean melanoma patients
S. Yun, K. Lee, Y. Park, S. Moon, H.S. Lee, G. Choe, K.S. Lee; KR

352P - Early safety from a phase 1, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIIB-IV melanoma (MEL)
N. Yamazaki1, H. Koga1, T. Kojima1, A. Tsutsumida1, K. Namikawa1, M. Yi2, K. Mera1, C. Pickett-Gies2; 1JP, 2CA/US

353P - Clinical and laboratory markers as predictors of Time to Treatment Failure (TTF) and Overall Survival (OS) in patients (pts) with mucosal melanoma (MM).

354P - 5HT3 receptor antagonists selectively kill melanoma cells
A. Barzegar Fallah, H. Alimoradi, S. Baird; NZ

355P - Efficacy and safety of weekly docetaxel regimen for advanced extramammary Paget’s disease: retrospective single institute analysis.
Y. Nakamura, I. Hirai, M. Ishii, Y. Kawakami, K. Tanese, T. Funakoshi; JP

356P - Knowledge, attitudes, and behaviors toward skin cancer among Marine Fisheries students of Udayana University, Bali
S.A. Suryantari, A. Satyarsa, I.G.A. Indriani, P. Sudarsa, L.M. Rusyati, M. Adiguna; ID

357P - Location of malignant melanoma in distal extremity draining to popliteal or epitrochlear sentinel lymph nodes
S. iinnai, K. Namikawa, E. Nakano, A. Takahashi, N. Yamazaki; JP

YO26 - Local disease control of nasal malignant melanoma achieved by administration of nivolumab followed by palliative radiation: a case report
T. Yamazaki, JP

Last update: 09-11-2018 02:52:09pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:40 - 18:40</td>
<td>YO28 - Malignant Melanoma of the Palate: Report of a Metastatic Case</td>
<td>M.V. Cruz-Ordinario, C.A. Boado, A. Gorospe; PH</td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>YO29 - Excellent response of nivolumab in patient with metastatic malignant melanoma of vagina: a case report</td>
<td>A. Maisrikrrod, A. Dechaphunkul; TH</td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>Palliative care</td>
<td></td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>360P - Patterns of practice for bone metastases in Japan - use of questionnaires to promote a multidisciplinary approach</td>
<td>N. Nakamura¹, Y. Sakai¹, N. Matsubara², K. Kakutani¹, T. Aksue¹, N. Kiyota³, H. Minami³; ¹JP, ²Chiba/JP, ³Hyogo/JP</td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>362P - Retrospective analysis of efficacy and safety of Cell-free and Concentrated Ascites Reinfusion Therapy in pancreatic cancer patients with malignant ascites</td>
<td>K. Harada¹, Y. Kobayashi², S. Nozawa¹, K. Sakurai¹, K. Suto¹, A. Yoshikawa¹, R. Sasaki¹, R. Abiko¹, H. Ebata¹, I. Sano¹, H. Oda¹, T. Miyagishima¹; ¹JP, ²Hokkaido/JP</td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>363P - A Randomized Controlled Trial of Mindfulness Breathing Exercise in Patients with Advanced Lung Cancer</td>
<td>C.S. Chai, S.-B. Tan, D. Ng, C.K. Liam, Y.K. Pang; MY</td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>364P - An Estimation of the Population-based Survival Benefit of First-course Chemotherapy for Advanced Incurable Cancer</td>
<td>V. Do, W. Ng, S. Jacob, G. Delaney, M. Barton; NSW/AU</td>
</tr>
<tr>
<td>18:40 - 18:40</td>
<td>365P - Palliative care as a part of national cancer control plan in Uzbekistan - first steps towards the solution</td>
<td>Y. Ziyaev, M. Tillyashaykhov, A. Yusupbekov, S. Abdujapparov, D. Egamberdiev, Y. Ten, H. Islamov; UZ</td>
</tr>
</tbody>
</table>
18:40 - 18:40 366P - Socioeconomic status and demographic assessment of advanced cancer patients in Palliative care department of a tertiary care centre: Observational study
G. Kumar, West Bengal/IN

18:40 - 18:40 Precision medicine

18:40 - 18:40 370P - Shaheenah Dawood MD1, Maroun Khoury2, Faraz Khan2, Falah Khatib1, Milicent Bello3, Annette Hamadi3, Houriya Kazim3, Rania Khoury4, Georges Nasioulas5, Aparna Dhar6
R. Khoury1, S. Dawood2, M. Khoury2, F. Khan2, F. Al Khatib2, M. Bello2, A. Hamadi2, H. Kazim2, A. Dhar3, G. Nasioulas4; 1LB, 2AE, 3IN, 4GR

18:40 - 18:40 371P - Clinical and molecular characteristics of ALK-rearranged Chinese lung cancer patients
Y. Fang, J. Shou, W. Han, H. Li, X. Zhou, D. Li, H. Cheng, H. Wang, F. Lou, S. Cao, H. Pan; CN

18:40 - 18:40 372P - Identification and validation of a Prognostic Signature in Malignant Pleural Mesothelioma
J.-G. Zhou, H. Ma; CN

18:40 - 18:40 373P - Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population
J. Lee1, A. Franovic2, T. Rich2, Y. Shiotsu2, V. Raymond2, R. Lanman2; 1KR, 2US

18:40 - 18:40 374P - Are We There Yet? A Critical Reflection of Asian Medical Oncologists on NGS-guided Precision Treatment in Asia 2018
A. Lai1, W.S. Seo Tho1, S.L. Poon1, K.T. Tan2, K. Tung2, J. Lee2; 1SG, 2TW

18:40 - 18:40 375P - Concordance study of between IBM Watson for oncology and real clinical practice for gastric, breast and ovarian cancer
J.G. Choi, KR

18:40 - 18:40 376P - Impact of single-gene and co-occurring mutations on TMB with potential implications for immunotherapy
T. Shou, H. Ma, F. Lan, W. Gu, W. Cui, B. Zhang, Y.-A. Dong; CN

18:40 - 18:40 377P - Application of a comprehensive platform technology for detection of cancer-associated genomic alterations and viral DNA in liquid biopsies
Y. Choudhury, H. Chen, F. Fadhlullah, D. Tan, K. Ng, W. Phyo, M.H. Tan; SG

18:40 - 18:40 378P - Circulating cell-free DNA molecular profiling among East Asian patients reveals activating MET alterations are common in diverse advanced cancer types
18:40 - 18:40 379P - Prevalence of pathogenic mutations in Korean hereditary breast-ovarian cancer

18:40 - 18:40 380P - Establishment of a patient-derived xenograft (PDX) model with malignant pleural effusion and its application

18:40 - 18:40 381P - The study of RET rearrangement in advanced primary non-small cell lung cancer and associated metastatic lesions

18:40 - 18:40 382P - Comparison of tumor mutational burden and pd-l1 between 2797 primary and metastatic breast cancer samples
S. Dawood1, K. Schuster2, R. Fedlman3; 1AE, 2CH, 3US

18:40 - 18:40 383P - Whether pericarcinomatous tissue of non-small cell lung cancer can serve as genetic background filter in next-generation sequencing analysis
Y. Zhang, L. Zhang, L. Chang, Y. Yang, W. Fang, Y. Guan, X. Xia, X. Yi; CN

18:40 - 18:40 384P - Incidence of Germline BRCA1 and BRCA2 mutations among Filipinos
F.V. Que, D. Ang, J.J. Andal, M. Madrid, R. Lo, M.S. Imasa, M.L. Enriquez, F. Tria Iv, L.K. Cabral, R. Dimalibot, R. Li; PH

18:40 - 18:40 385P - Clinical feasibility of pancreaticoduodenectomy in different ages
Z. Wei, T. Qing, D. Wei; CN

18:40 - 18:40 386P - TP53 GOF mutations predict good response and prolonged survival to bevacizumab treatment in metastatic colorectal cancer

18:40 - 18:40 387P - Radiation dose to contralateral parotid during treatment of carcinoma buccal mucosa
R. Narayanasamy, S. Thiagarajan, S. P, K. Perumal; IN

18:40 - 18:40 388P - ALK rearrangment in pulmonary sarcomatoid carcinoma: a retrospective study of the real world
18:40 - 18:40 389P - Risk factors of nivolumab-induced pneumonitis in patients with solid tumors
T. Yamaguchi1, T. Hasegawa1, N. Hanai1, Y. Inaba1, K. Muro2, T. Hida1; 1JP, 2Aichi/JP

18:40 - 18:40 390P - Analysis of RET rearrangement non-small cell lung cancer cell blocks from pleural effusion

18:40 - 18:40 391P - Mismatch repair deficiency testing for immunotherapy in metastatic cancers: a single centre study from India
T. Sood1, A. Rauthan1, P. Patil1, S. Kulkarni1, S.P. Somashekhar1, S. Zaveri2; 1IN, 2Karnataka/IN

18:40 - 18:40 392P - Candidate markers of homologous recombination deficiency for triple negative breast cancer
K. Havrysh1, G. Mukhametshina2, S. Petrov2, S. Safina2, R. Kiyamova2; 1UA, 2RU

18:40 - 18:40 393P - The landscape and genomic characteristics in BRAF V600E wild type papillary thyroid carcinoma
M.-Y. Fang, C. Xu, W.-X. Wang, M.-J. Wu, G. Chen, M.-H. Ge; CN

18:40 - 18:40 394P - Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer.

18:40 - 18:40 395P - A study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients
C. Chen, X. Liu, C. Han; CN

18:40 - 18:40 Public policy

18:40 - 18:40 400P - Do Time, distance and economic factors influence stage of presentation of malignancies?? Experience from a Regional cancer center in India
N. Ballari, T. Jindia, L. Annam, R. Miriyala, S. Ghoshal; IN

18:40 - 18:40 401P - Survey of Diet and Physical Activity in New Cases of Young Breast Cancer Patients in Taiwan

18:40 - 18:40 402P - Retrospective analysis of risk factor of injection site reaction induced by infusion of cisplatin plus vinorelbine
N. OZAWA, T. Hase, T. Hatta, A. Sagara, K. Ichikawa, M. Miyazaki, M. Ando, K. Yamada, Y. Hasegawa; JP

18:40 - 18:40 403P - Knowledge and Attitudes of Productive Age Women About Visual Inspection with Acetic Acid (VIA) Test in Early Screening of Cervical Cancer in Tihingan village, Klungkung, Bali

18:40 - 18:40 404P - Clinical spectrum and treatment outcomes of HIV associated cancers in a tertiary care center in South India
S. Elumalai, K. Kannan, R. Gopal, S. Sundararajan; IN

18:40 - 18:40 405P - The Impact of Awareness Program on the Knowledge, Attitude and Practice of Breast self examination among Female Healthcare workers in a Tertiary Hospital: An Interventional Study
S.R.A. Kwak, PH

18:40 - 18:40 Sarcoma
R. Quek¹, H. Loong²; ¹SG, ²HK

18:40 - 18:40 409P - Prognostic factors for post-progression survival after trabectedin treatment in patients with advanced soft tissue sarcoma

18:40 - 18:40 410P - FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: clinical and molecular pathology findings of two cases
M. Lacambra¹, H. Loong¹, K.F. To¹, X. Feng², G. Taylor², E. Pleasance², J. Laskin², M. Marra², J. Griffith¹, H.Y.M. Yeung¹, K.-C. Wong¹, C. Chow¹, S. Kumta¹, W.H.A. Ng¹, T. Tse¹, C. Tong¹, T. Ng²; ¹HK, ²BC/CA

18:40 - 18:40 411P - Molecular-genetic markers and remote results in osteosarcoma treatment

18:40 - 18:40 412P - Comprehensive mRNA-based screen for tyrosine kinase fusions and a de novo alternative transcription initiation site in soft tissue sarcomas

18:40 - 18:40 413P - Clinical benefits of later line trabectedin and eribulin treatment for soft tissue sarcoma (STS) after pazopanib treatment from Nishinomiya Sarcoma Cohort Study (NSCS)
H. Narahara¹, M. Morimoto², E. Tanaka², S. Ueda², Y. Yasunaga², Y. Inui², K. Takahashi², S. Kawata²; ¹Hyogo/JP, ²JP
414P - Treatment outcomes of adult osteosarcoma in Srinagarind Hospital
P. Eiamprasaporn¹, A. Sookprasert², K. Wirasorn², P. Ungareeewittaya¹, J. Chindaprasirt²; ¹TH, ²Mueang Khon Kaen District/TH

415P - A clinical outcome of dedifferentiated Low-grade osteosarcoma based on molecular pathological confirmation
E. Kobayashi, S. Toki, A. Yoshida, A. Kawai; JP

416P - Ewing Sarcoma in Adults: Demystifying Experience from a Developing Nation
R. Ambalathandi¹, S. Gundeti¹, B. Stalin², M. Konatam¹, N. Palukuri¹, R. Yedla¹; ¹IN, ²Andhra Pradesh/IN

417P - Oncological outcome of extremity synovial sarcomas treated with multimodality management
A. Gulia, A. Puri, S. Laskar, B. Rekhi; IN

418P - Oxidized low density lipoprotein receptor 1 promotes lung metastases in osteosarcoma through regulating the epithelial-to-mesenchymal transition
J. Dylan¹, S. Jiang², H. Long², Q. Luo²; ¹Guangdong/CN, ²CN

419P - Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retrospective analysis
K. Gupta, S. Parthiban, S. Kumar, S. Srinivas, D. Vallathol, R. Chana, G. Grewal, N. Rathnasamy, A. Goel, J. Bajpai; IN

YO30 - Extra-Gastrointestinal stromal tumor and tumor lysis syndrome, A case-report
T. Sanlung¹, K. Wirasorn²; ¹TH, ²Mueang Khon Kaen District/TH

YO31 - Reduced and re-escalated dose of sunitinib was adequately effective against gastrointestinal stromal tumor of the small intestine: a case report
M. Ogata¹, H. Satake², T. Ogata¹, Y. Hatachi¹, H. Yasui¹; ¹JP, ²Hyogo/JP

YO32 - A Case Report: Life-threatening giant cell tumor of bone with coexisting primary hyperparathyroidism initially misdiagnosed as brown tumor treated with denosumab.
A. Phongphithakchai, S. Sakdejayont; TH

YO33 - Dermatofibrosarcoma Protuberans of Thigh: A Case Report
S. m, G. Usha Shree, N. Rao, R. Reddy; IN

Supportive care
D. Keefe¹, K. Lee², C. Steer³; ¹SA/AU, ²NSW/HK, ³VIC/AU
18:40 - 18:40  **424P** - **Clinical Factors associated with satisfaction of cancer patients for the treatment of opioid-induced constipation: A post hoc analysis utilizing outcomes of nalbuphine Phase 3 study**
H. Ishiki, E. Satomi, Y. Tada, T. Yokota, H. Sato, M. Okamoto, I. Osaka; JP

T. Noriyuki1, H. Imai1, S. Fumita1, T. Harada1, M. Gamoh2, Y. Akashi1, H. Sato1, Y. Kizawa1, A. Tokoro1; 1JP, 2MiyagiJP

18:40 - 18:40  **426P** - **Nutritional supplement ONCOXIN to maintain appetite, body mass and quality of life in patients with advanced cancer on chemotherapy**
M. Kopp1, I. Koroleva1, E. Bilan1, E. Sanz2, F. Petrovskiy1; 1RU, 2ES

18:40 - 18:40  **427P** - **Association between dietary patterns with disease recurrence in Thai colorectal cancer patients**
V. Kunnavuttivanich, P. Pramyothin, S. Ithimakin; TH

18:40 - 18:40  **428P** - **Efficacy of single dose NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of nausea in patients receiving high dose cisplatin**
A. Dechaphunkul1, S. Lu2, S. Olivari3, L. Zhang2; 1TH, 2CN, 3CH

18:40 - 18:40  **429P** - **A Randomized, Double Blind, Placebo-Controlled Study Evaluating Efficacy of Combination Olanzapine, Ondansetron and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Doxorubicin plus Cyclophosphamide**
W. Nipondhkit, TH

18:40 - 18:40  **430P** - **The Prospective Multicenter Study of Relation between 5-HIAA / Substance P plasma Concentration Transition and Nausea / Vomiting in Patients with Gastrointestinal Cancer Receiving Moderately Emetogenic Chemotherapy (MEC).**
K. Sawada1, Y. Komatsu2, T. Muranaka2, S. Nakano1, Y. Kawamoto1, H. Nakatsumi1, S. Yuki2, M. Dazai2, T. Saiki1, A. Ishiguro1, M. Tateyama1, K. Ono1, S. Ohnishi1, N. Sakamoto1; 1JP, 2HokkaidoJP

18:40 - 18:40  **431P** - **A randomized study comparing two different training programs**
A. Bellens, B. Sabbe, P. van Dam; BE

18:40 - 18:40  **432P** - **Resilience in adult cancer care: A review and concept analysis**
D. Luo1, M. Eicher2, K. White3; 1AU, 2CH, 3ACT/AU

18:40 - 18:40  **433P** - **A pilot study of exercise intervention during chemotherapy in patients with metastatic cancer**
18:40 - 18:40 434P - A phase II study to assess the immunogenicity and optimal timing of 13-valent pneumococcal conjugated vaccination during adjuvant chemotherapy
W.K. Bae, KR

18:40 - 18:40 435P - Title: Primary Prophylaxis For Febrile Neutropenia - Is It Really Required For AC Chemoregimen In Breast Cancer Patients?
N. Palukuri, IN

18:40 - 18:40 436P - Identifying predictive factors for severe anemia in cancer patients treated with cytotoxic chemotherapy
B. Mofid, A. Razzaghdoust, P. Peyghambarlou; IR

18:40 - 18:40 437P - Cost simulation for the US of febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim in lung cancer

18:40 - 18:40 438P - Preventive Role of Beta Blockers and Renin-Angiotensin Inhibitors in Anthracycline-induced Cardiotoxicity among Adult Cancer Patients: A Meta-Analysis
D.B. Sacdalan, M.D. Tiongson, K.A. Mondragon, L. Abrahan, Iv, J. Añonuevo, G. Fernando, F.E. Punzalan; PH

18:40 - 18:40 439P - Pain control among cancer patients receiving strong opioids and their perspective towards opioids in a developing country with a diverse multicultural background
D. Lee, D. Kiu, V. Pei Jye; MY

18:40 - 18:40 440P - A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting. (ESPRESSO-02/HGCSG1602)
M. Nakamura1, T. Muranaka2, M. Yagisawa1, Y. Kawamoto1, S. Yuki2, A. Ishiguro1, M. Dazai2, S. Sogabe1, K. Harada1, Y. Kobayashi2, T. Miyagishima1, N. Okamura1, Y. Tsuji2, S. Terae1, K. Ono1, Y. Komatsu2; 1JP, 2 Hokkaido/JP

M. Kato, JP

18:40 - 18:40 442P - CGA directed interventions in Asian geriatric oncology patients
M. Wang, F. Ho, Y.S. Ng, B.C. Tai, W.C. Yong, S.L.A. Pang; SG
T. Oguri¹, M. Hiraide², T. Shiga², C. Yasuda², M. Nishio², S. Takahashi²; ¹Aichi/JP, ²JP

18:40 - 18:40 444P - Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma

18:40 - 18:40 445P - Correlation between Lymphocyte-Monocyte Ratio and Hand Grip Strength in Breast Cancer Patients before Chemotherapy
A. Kurniawan, R. Hatma, A. Adisasmita, N. Soetandyo, F. Witjaksono, H. Putri, D. Widjaja; ID

18:40 - 18:40 446P - What do oncologists think patients with incurable cancer should be told about their prognosis?
A. Vasista¹, M. Stockler², A. Martin², N. Lawrence², B. Kiely²; ¹AU, ²NSW/AU

18:40 - 18:40 447P - Herbal product and dietary supplement intake among patients at the Philippine General Hospital (PGH) medical oncology clinic: a cross-sectional survey.
R.E. King, D. Sacdalan, R.R. Angeles; PH

18:40 - 18:40 448P - Can we estimate the risk of chemotherapy toxicity in Indian Geriatric patient population and utility of CRASH (Chemotherapy risk assessment scale for high age patients) score?
A. Mittal, A. Agarwal, R. Rangaraju, S. Batra, C. Gouda D, S. Qureshi; IN

18:40 - 18:40 449P - A Study of Adherence to oral temozolomide chemotherapy in central nervous system tumors
S. VALLATHOL, IN

18:40 - 18:40 450P - Prescreening of immune-related adverse events in our institute
T. Sone, T. Murai, K. Itaya, Y. Koike, Y. Ono, M. Nakamura; JP

18:40 - 18:40 451P - Epidemiology of AYA(adolescents and young adults) cancer in National Institute of Cancer Research and Hospital(NICRH),Dhaka, Bangladesh.
A.A.M. Khan, P.S. Akthar; BD

18:40 - 18:40 452TiP - A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy. (ExCAVE study)
M. Nakamura¹, M. Yagisawa¹, T. Saiki¹, A. Ishiguro¹, K. Sawada¹, S. Yuki², T. Sasaki¹, T. Ando¹, H. Ohori³, M. Kotaka⁴, M. Muto¹, Y. Shindo¹, K. Nakashima¹, A. Hosokawa¹, A. Doi⁵, N. Izawa¹, Y. Sunakawa¹, A. Satoh¹, K. Ono¹, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Miyagi/JP, ⁴Hyogo/JP, ⁵Chiba/JP
Thoracic tumours, early stage

18:40 - 18:40  
**454P - The PD-L1 expression in surgically resected lung adenocarcinoma: Its correlations with the prognosis, driver oncogene alterations and clinicopathological features**  
K. Takamochi, T. Hayashi, K. Hara, K. Suzuki; JP

18:40 - 18:40  
**455P - Association Between Pre-Existing Conditions and Driver Gene Profiles/Immune Contextures in NSCLC: A Large-Sample Analysis**  
W. Liang, C.C. Li, Z. Wang, Y. He, J. He; CN

18:40 - 18:40  
**456P - Optimal Starting Age for Lung Cancer Screening with Low-dose CT: A Population Level Analysis**  
C.C. Li, H. Liang, Y. Zhao, Y. Wen, G. Qiu, N. Zhong, J. He, W. Liang; CN

18:40 - 18:40  
**457P - Impact of FDG PET/CT in selection of patients for adjuvant chemotherapy in resection margin negative stage IB and IIA (T2bN0) non-small cell lung cancer**  
H.L. Park, I.R. Yoo, S. Park, S.H. Boo; KR

18:40 - 18:40  
**458P - Rate of pathological N2 nodes among patients of NSCLC with cN0/cN1 nodal status on CECT scan - A study from tertiary care hospital in India**  
B. Bansal, M. Gowda, V. Kumar, S. Deo, S. Bhirowal, D. Jain, P. Malik, S. Jee Bharati, M. Yadav, S. Kumar; IN

18:40 - 18:40  
**459P - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung**  
Y. Wang, CN

18:40 - 18:40  
**460P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Elderly Patients with Limited Stage Small Cell Lung Cancer**  
S. Abdulaziz, EG

18:40 - 18:40  
**461P - Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy**  

18:40 - 18:40  
**462P - Circular RNA Profiling and Its Potential for Esophageal Squamous Cell Cancer Diagnosis and Prognosis**  
Q. Cao, L. Fan, J. Zhu, J. Zhang, B. Li; CN

18:40 - 18:40  
**463P - Asthma and Risk of Lung Cancer: A Mendelian Randomization Study**  
H. Zhou¹, Y. Zhang¹, W. Fang¹, Y. Huang¹, Y. Yang¹, S. Hong¹, G. Chen¹, S. Zhao¹, J. Liu¹, H. Zhao¹, Z. Li²; ¹CN, ²Guangdong/CN
18:40 - 18:40  YO35 - Thymic large cell neuroendocrine carcinoma- a rare and aggressive tumor: case report
W. laosuangkool, E. Sirachainan; TH

18:40 - 18:40  YO36 - A Case of Good Syndrome: A Rare Acquired Immunodeficiency Associated with Thymoma
S. Sakchinabut, C. Sookthon, P. Phichai Chansriwong; TH

18:40 - 18:40  Thoracic tumours, locally advanced

18:40 - 18:40  467P - Correlation between PD-L1 expression and clinicopathological characterization in NSCLC
Y. Jin, CN

18:40 - 18:40  468P - Relationship of the level of soluble PD-L1 and its relevant proteins in peripheral blood with the prognosis of patients with NSCLC
G. Bai, Y. Xu, M. Wang; CN

18:40 - 18:40  469P - Application of Next Generation Sequencing in Pleural Effusion Molecular Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay
C. Xiang, R. Zhao, S. Ma, L. Guo, Y. Han; CN

18:40 - 18:40  470P - Clinical and Pathological Characteristics and Survival Analysis of NSCLC Patients with Skip Metastasis in Stage pN2/III
L. Zhang, CN

18:40 - 18:40  471P - Effect of second-line ramucirumab in East Asian patients with refractory and aggressive disease: Subgroup analysis from REVEL and JVCG trials in non-small cell lung cancer
K. Yoh1, K. Nakagawa1, G.-C. Chang2, Y. Hosomi1, T.-C. Hsia2, T. Tamura1, R. Cheng2, R. Varea3, S. Enatsu1, A. Hayden Zimmermann4, J.-Y. Shih2; 1JP, 2TW, 3ES, 4AL/US

18:40 - 18:40  472P - Plasma KRAS Mutation in Indonesian Lung Cancer Patients with Smoking History, Treated with Chemotherapy
N. Masykura1, S. Andarini2, E. Syahruddin Spp K1, J. Zaini1, A. Hudoyo1, Y. Santoso1, A. Mirandari3, A.R. Utomo1; 1ID, 2DKI Jakarta/ID, 3GB

18:40 - 18:40  473P - ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): subpopulation analyses by poor performance status (PS), elderly, uncommon EGFR mutations
M. Provencio1, P. Cheema2, J. Vansteenkiste3, B.C. Cho4, C. Zhou5, J. Yu5, C. Martin6, K. Park4, Y. He5, Y. Hu5, D. Vicente1, M. Miranda7, J. Rigas8, F. de Marinis9; 1ES, 2CA, 3BE, 4KR, 5CN, 6AR, 7GB, 8MD/US, 9IT

Last update: 09-11-2018 02:52:09pm
18:40 - 18:40 474P - Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC
S. Thongprasert1, S. Geater1, D. Clement2, A. Abdelaziz3, J. Reyes-Igama4, D. Jovanovic5, A. Alexandru2, M. Schenker2, V. Sriuranpong1, P. Serwatowski6, S. Suresh7, A. Cseh8, R. Gaafar3; 1TH, 2RO, 3EG, 4PH, 5RS, 6PL, 7SG, 8AT

18:40 - 18:40 475P - Radiotherapy With Continued EGFR-TKIs for Oligoprogressive Disease in Non-Small Cell Lung Cancer: A Real-World Study
F. Wu1, S. Wu2, H. Hu2; 1Hunan/CN, 2CN

18:40 - 18:40 476P - Clinicopathological Features of ALK Protein in 9889 Non-small-cell Lung Cancer Specimens and Genomic Rearrangement Identified by Capture-based Next-generation Sequencing: a Chinese Retrospective Analysis
R. Zhao, J. Zhang, Y. Han, J. Shao, L. Zhu, C. Xiang, Q. Zhang, H. Teng, G. Qin, L. Zhao, M. Ye, J. Zhao, W. Ding; CN

18:40 - 18:40 477P - Meta-analysis comparing incidence of Grade 3/4 neutropenia with ALK inhibitors and chemotherapy, in patients with NSCLC
A. Krendyukov1, R. Arani2, N. Mathieson1, B. Rapoport3; 1DE, 2NJ/US, 3ZA

18:40 - 18:40 478P - A Large-scale Retrospective Study on ROS1 Fusion in Lung Carcinoma in Chinese Population.
Q. Zhang, Y. Han, J. Zhang, J. Shao, L. Zhu, R. Zhao; CN

18:40 - 18:40 479P - Bevacizumab-Induced RadioSENSITIZATION in Small Cell Lung Cancer
J. Bonner1, H. Trummell2; 1US, 2AL/US

18:40 - 18:40 480P - Tracheal adenoid cystic carcinoma: A systematic review and Meta-analysis
S. Mallick, P. Giridhar, G. Rath; IN

18:40 - 18:40 481P - The effectiveness of CRT combined with esophagectomy for cT4b esophageal SCC
S. Hamasu, D. Manaka; JP

18:40 - 18:40 482P - treatment experience of thymoma & thymic carcinoma in tertiary cancer institute in india
V. Tirumala1, M. Suresh Babu1, K. Govind Babu1, D. Lokanatha1, L. Jacob1, K.N. Lokesh2, A. Rudresha2, L. Rajeev1, S. Saldanha2, G. Giri1; 1IN, 2Karnataka/IN

18:40 - 18:40 YO37 - The usefulness of radiotherapy for intubated patients with squamous cell carcinoma of the lung.
S. Hiraoka, K. Ogura, Y. Kosaka, T. Imagundai, T. Hattori, T. Ogata, M. Kokubo; JP

18:40 - 18:40 Thoracic tumours, metastatic
18:40 - 18:40 494P - Hippo-YAP Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer
P. Sun, H. Gao; CN

18:40 - 18:40 495P - Serum EGFR1 and EGFR2 expression in Non Small Cell Lung Cancer patients.
M.M.A. Beg, IN

18:40 - 18:40 496P - Clinical application of plasma mitochondrial DNA content in lung cancer patients
L. Zhang, CN

18:40 - 18:40 497P - Neutrophil Extracellular Traps Promote Lung Cancer Invasion and Migration In Response to Severe Infection
L. Zhang, CN

18:40 - 18:40 498P - Retrospective evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with clinical and demographical data from a tertiary care institute of northern India.

18:40 - 18:40 499P - Mutation status and targeted therapeutic efficacy of advanced non-small cell lung cancer: A real-world study of NSCLC in China (preCAPTRA-LUNG)

18:40 - 18:40 500P - Efficacy of Icotinib in Advanced Lung Squamous Cell Carcinoma
S. Liang, M. Wang, Y. Xu, F. Tan, L. Ding, Y. Ma; CN

18:40 - 18:40 501P - Phase II study of Nedaplatin plus Amrubicin in patients with untreated, advanced or relapsed Squamous cell lung cancer

18:40 - 18:40 502P - Apatinib plus S-1 as Second-Line or Laterline Treatment for Advanced Squamous Cell Lung Carcinoma
Q. Shu1, L. Xia1, J. Zhou1, Z. Wang1, L. Sheng1, G. Wang1, L. Wang1, X. Cheng1, F. Wang1, F. Kong2, F. Zhao1, X. Li1, B. Ye1, L. Mei1, Y. Liu1, L. Pan1, J. Xie1, G. Cheng1, X. Li1; 1CN, 2CX

18:40 - 18:40 503P - Clinical experiences of cytotoxic chemotherapy in patients with lung cancer complicated by interstitial pneumonia who were treated with pirfenidone simultaneously: A retrospective observational study in single institution
Y. Yano, K. Nishida, M. Ishijima, T. Uenami, Y. Akazawa, T. Yamaguchi, M. Mori; JP
18:40 - 18:40 504P - Association of Systemic Inflammation With Survival in EGFR wild-type lung cancer
X. Chen, L. Zhang, X. Liu; CN

18:40 - 18:40 505P - Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT02780778)
Z. Pan, C. Wang, G. Xie, D. Liu, Z. Yan, Y. Li, Z. Jiang, B. Wang, L. Li; CN

18:40 - 18:40 506P - Efficacy of local therapy for patients with oligometastatic non-small cell lung cancer

18:40 - 18:40 507P - Investigating Tumour Evolution in a Single Patient with Disseminated Cancer
T. Robb, C. Blenkiron, P. Tsai, K. Parker, A. Drummond, M. Black, A. Gavryushkin, B. Woodhouse, P. Houseman, E. Coats, P. Shields, S. Fitzgerald, D. Wright, R. Tse, N. Kramer, C. Barker, Y. Triggs, S. Stables, B. Lawrence, C. Print; NZ

18:40 - 18:40 508P - Oncogenic driver mutation analysis in lung adenocarcinoma: a single center study in India
S. Kulkarni1, A. Rauthan1, P. Patil1, T. Sood1, S. Somashekhar1, S. Zaveri2; 1IN, 2Karnataka/IN

18:40 - 18:40 509P - Treatment (Tx) patterns in patients (pts) with lung cancer starting 1st or 2nd generation (1G/2G) EGFR-TKI: a US insurance claims database analysis
J. Gray1, B. Thakrar2, P. Sun2, S. Maclachlan2, N. Chehab3, D. Potter2; 1FL/US, 2GB, 3US

18:40 - 18:40 510P - Characteristics and outcome of small cell lung cancer patients (SCLC) transformed from adenocarcinoma after tyrosine kinase inhibitors treatment
B. Zhang, J. Xu, S. Wang, Y. Zhang, J. Qian, R. Qiao, J. Lu, L. Zhang, Y. Zhao, B. Han; CN

18:40 - 18:40 511P - AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): updated PhII results including overall survival (OS)
C. Zhou1, M. Wang1, Y. Cheng2, Y. Chen3, Y. Zhao1, Y.-K. Shi1, M.-J. Ahn4, Y. Lu5, M. Shi1, J.-Y. Han4, S.-W. Kim4, H.-L. Zhang1, G. Chen1, H. Li1, J. Wang1, Y.-L. Wu1; 1CN, 2Jilin/CN, 3Hubei/CN, 4KR, 5Sichuan/CN

18:40 - 18:40 512P - Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

Last update: 09-11-2018 02:52:09pm
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
P.-L. Su, Y.-L. Wu, W.-Y. Chang, W.-C. Su, S.-C. Yang, C.-C. Lin; TW

Co-occurring Alterations in Driver Genes Impact on EGFR-Targeted Therapy Among Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): phase 2 data
Y.-L. Wu1, J. Zhou2, S. Lu2, Y. Zhang3, J. Zhao2, H. Pan2, Y.-M. Chen4, C.-F. Chian5, R. Bruns6, A. John6, J. Scheele6, Y. Cheng7; 1Guangdong/CN, 2CN, 3Zhejiang/CN, 4TW, 5, 6DE, 7Jilin/CN

Phase II Trial of Afatinib in Elderly Patients over 75 Years of Age with EGFR mutation positive NSCLC

A real world study of osimertinib: ASTRIS 2nd DCO Korean subgroup analysis

Outcomes of EGFR-TKIs for patients with non-small cell lung cancer harboring EGFR mutations with poor performance status
K. Hashimoto, Y. Okuma, T. Hakozaki, K. Watanabe, Y. Hosomi; JP

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) - Tyrosine Kinase Inhibitors (TKI) in Elderly Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

Brain surgery for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases
H.H. Lee, M.-Y. Huang; TW

Real World Data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation.
K. Tanaka1, N. Inui1, K. Asada1, T. Abe1, O. Hataji1, S. Hayai1, K. Ito1, K. Imaizumi1, T. Kimura2, A. Kubo1, E. Kuni1, K. Murotani1, M. Okuno1, Y. Oya1, J. Shindoh1, H. Taniguchi1, T. Tsuda1, T. Yamaguchi1, T. Hida1, T. Suda1; 1JE, 2Aichi PrefectureJP
18:40 - 18:40 523P - Real World Data on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) use in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations in Singapore

18:40 - 18:40 524P - EGFR mutation in Middle East and Africa is it really lower than in asiatic NSCLC ?
Z. Benbrahim, H. Bedoudou, N. Mellas; MA

C.H. Chen, M.-Y. Huang, I.-W. Chong; TW

18:40 - 18:40 526P - Correlation between the response to crizotinib and concomitant genetic alterations in advanced lung cancer patients with ALK rearrangement
X. Liu, M. Chen, Y. Xu, J. Zhao, W. Zhong, M. Wang; CN

18:40 - 18:40 527P - Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong
H. Loong, C. Wong, L. Leung, C.P.K. Chan, A. Chang, M. Gibbs; 1HK, 2AE

18:40 - 18:40 528P - The impact of continuing ALK inhibitors beyond initial disease progression on clinical outcome in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter retrospective analysis

18:40 - 18:40 529P - The management and outcome of crizotinib resistant patients: comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI.
S. Majumdar, A. Agarwal, V. Noronha, A. Joshi, V. Patil, R. Kumar, K. Prabhash; IN

18:40 - 18:40 530P - Comparative efficacy of first-line ceritinib and alectinib in advanced ALK+ NSCLC: a cross-study indirect comparison

18:40 - 18:40 531P - Clinical Experience in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases in China
Y. Han, K. Ren, H. Zhang, L. Sun, X. Ren; CN

18:40 - 18:40 532P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?
18:40 - 18:40 533P - PD-(L)1 Inhibitors VS. Chemotherapy VS. Their Combination in Front-line Treatment of NSCLC

H. Liang, D. Chen, Z. Liu, J. He, W. Liang; CN

18:40 - 18:40 534P - Pre-existing antibody profiles related to immune-related adverse events in advanced non-small-cell lung cancer patients treated with anti PD-1 antibody


18:40 - 18:40 535P - Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody


18:40 - 18:40 536P - Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild type advanced NSCLC

P. Xiao¹, R. Yu², X. Wu³, Y. Shao², Y.-L. Wu¹, Q. Zhou¹; ¹CN, ²CA, ³ON/CA

18:40 - 18:40 537P - The financial toxicity of non-small lung cancer treatment: the optimization of first and second-line therapy with immune check point inhibitors

J. Giuliani, A. Bonetti; IT

18:40 - 18:40 538P - Lung cancer vaccine - Experiences in Serbia

Z. Andric; RS

18:40 - 18:40 539P - Profiling of Immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small-cell lung cancer in real world.


18:40 - 18:40 540P - Clinical Outcomes in Non-Small Cell Lung Cancer Patients with Ultra-high Expression of Programmed Death Ligand-1 Treated with Pembrolizumab as First-line Therapy: A Retrospective Multicenter Cohort Study


18:40 - 18:40 541P - Gold fiducial tracking using Cyberknife in adrenal metastasis from Small cell lung cancers

G. Lohith, B.S. Ajai Kumar; IN
542P - Prophylactic cranial irradiation in patients with extensive-stage small-cell lung cancer (ES-SCLC): an updated tertiary cancer centre experience
M. Naidoo, F. Lin, M. Jameson, K. Shelly, A. Srivastava; NZ

543P - Investigation and Analysis of Nutritional Status of Patients With Lung Cancer
X. Chen, L. Zhang, X. Liu; CN

544P - Lung Cancer in Adolescent & Young Adults: Single Center Experience from Eastern India
B. Biswas, D. Dabkara, S. Ganguly, J. Ghosh; IN

545tiP - Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study)

546tiP - Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); a phase 2 trial in progress
P. Paik1, H. Sakai2, R. Bruns3, J. Scheele3, J. Straub3, E. Felip4; 1NY/US, 2JP, 3DE, 4ES

YO38 - Concurrent nivolumab and radiotherapy in treatment of lung squamous cell carcinoma
D.W. Lee1, G.F. Ho2; 1MY, 2Wilayah Persukutuan/MY

YO39 - Adenocarcinoma lung with sphenoidal metastasis
M. Behera1, L. Soy2, F. Ansari2, N. Panda2, L. Sarangi2; 1Delhi/IN, 2IN

YO40 - Osimertinib in the Treatment of Leptomeningeal Disease in T790M-negative, EGFR-mutated NSCLC: A Case Report
L. Kasherman1, J. Chen2, H. Soudy1; 1AU, 2NSW/AU

YO41 - Hemodynamic instability caused by cardiac metastases of non-small cell lung cancer- case studies

YO43 - The long term survival of a 78 year old female diagnosed with Malignant Epithelial Mesothelioma with peritoneal disease on Pembrolizumab plus Pemetrexed and Carboplatin: a case report
K.R. Oracion, G. Cornelio; PH

General interest
18:40 - 18:40 548P - Can we improve cost effectiveness of oncology clinical trials workflow? A prospective RECIST 1.1 study
H. Beaumont, A. Iannessi, C. Klifa, S. Patriti; FR

18:40 - 18:40 549P - Clinical association of antibiotics in immune check point inhibitors for advanced cancer treatment
H. Kim, I.-H. Kim; KR

18:40 - 18:40 550P - Effect of Reasons for Screen Failure (RFSF) on Standard of Care in Cancer Patients Screened for Clinical Trials
C. Tiu1, Z. Loh1, C. Gan2, J. Hakanson2, H. Gan2, T. John2, E. Hawkes1; 1AU, 2VIC/AU

18:40 - 18:40 551P - The reporting quality of prediction models in oncology journals: a systematic review

18:40 - 18:40 552P - Survival patterns of pediatric neuroblastoma at different primary sites
A. Diab, I. Uthman; EG

18:40 - 18:40 553P - Efficacy of chemotherapy for elderly patients with extrapulmonary neuroendocrine carcinomas
C. Funasaka, O. Yasushi, Y. Kanemasa, T. Shimoyama; JP

18:40 - 18:40 554P - Rational Combinations of Active and Passive Immunotherapy Mobilize Immune and clinical responses in terminal cancers
R. Ruan1, Q.Z. Ruan2; 1CN, 2AL/US

18:40 - 18:40 555P - Clinical Features and Outcomes of Carcinoma of Unknown Primary Site: A single center experience
S. Gohar1, S. Al-Hassanin2, S. Soliman2; 1Menoufia Governorate/EG, 2EG

18:40 - 18:40 556P - Surgery for Nonhepatic malignancy in Cirrhotic Patients; 5 year Single Center Experience in India
S. Galodha, S. Bains; IN

B. Yadav1, C. Bihari2; 1Rohini/IN, 2IN
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Hall</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:15</td>
<td>Young Oncologist session</td>
<td>Vesalius</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15 - 10:00</td>
<td>Challenge Your Expert session</td>
<td>First line treatment in a fit advanced NSCLC patient with PD-L1 expression of 60%</td>
<td>404</td>
<td>Shun Lu, CN</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>First line treatment in a fit advanced NSCLC patient with PD-L1 expression of 60%</td>
<td>S. Novello, IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Discussion led by</td>
<td>Discussion led by</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Lu, CN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
09:15 - 11:15  Type: Special Session  Title: Working together: Illustration of combined modalites  Chair: Françoise Mornex, FR; Suresh Senan, NL

09:15 - 09:30  Early stage breast cancer: Case presentation 1: What is the recommended surgical approach?  C.W. Chan, SG

09:30 - 09:45  Early stage breast cancer: Is there a place for radiation after surgery?  F. Lim, SG

09:45 - 10:00  Lung SABR: Case presentation: Imaging and delivery techniques

10:00 - 10:15  Lung SABR: Post-SABR radiological evaluation: IASLC paper  S. Senan, NL

10:15 - 10:30  Castration-resistant prostate cancer: Case presentation: Indications for SABR, treatment planning and delivery techniques  M.L.K. Chua, SG

10:30 - 10:45  Castration-resistant prostate cancer: Is there a need for combined medical treatment?  R. Kanesvaran, SG

10:45 - 11:00  Esophageal and EG junction: How can the Medical Oncologist contribute?  F. Lordick, DE

11:00 - 11:15  Esophageal and EG junction: Clinical case presentation: Esophageal cancer treatment strategy, imaging and radiation delivery techniques  T. Leong, AU

Last update: 09-11-2018 02:52:09pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Content</th>
</tr>
</thead>
</table>
| 09:15 - 10:15 | **Type:** ESMO Colloquium  
**Title:** ESMO COLLOQUIUM - Metastatic gastric and oeso-gastric junction cancers  
Room 324 |
| 09:15 - 09:20 | **Introduction**  
K. Muro, Aichi/JP |
| 09:20 - 09:30 | **1st line treatment options for patients without a biomarker driven option**  
L.-T. Chen, TW |
| 09:30 - 09:40 | **Biomarker driven option in 1st line treatment options**  
M. Ng, SG |
| 09:40 - 09:50 | **2nd and later lines of treatment: What are the options?**  
F. Lordick, DE |
| 09:50 - 10:00 | **Is there some hope from immunotherapy in metastatic gastric cancer?**  
Y.-J. Bang, KR |
| 10:00 - 10:10 | **What’s new in the guidelines?**  
K. Muro, Aichi/JP |
| 10:10 - 10:15 | **Conclusions**  
F. Lordick, DE |
| 09:30 - 11:00 | **Type:** Educational session  
**Title:** Challenges in head and neck oncology  
Hall 405  
Chair: Christophe Le Tourneau, FR |
| 09:30 - 09:55 | **Hyperprogression following immunotherapy: Myth or reality?**  
C. Le Tourneau, FR |
| 09:55 - 10:20 | **The role of plasma EBV DNA in management of nasopharyngeal cancer**  
A. Chan, HK |
| 10:20 - 10:45 | **Surgery for low-risk HPV positive head and neck cancer**  
C. Simon, CH |
| 10:45 - 11:05 | **Discussion** |
09:30 - 09:35
**345O - The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors**
J. Lai-Kwon¹, C. Khoo², S. Lo³, D. Milne¹, M. Mohamed¹, J. Raleigh¹, K. Smith¹, K. Lisy¹, S. Sandhu¹, M. Jefford¹; ¹VIC/AU, ²AU, ³ACT/AU

09:35 - 09:40
**346O - PD-L1 expression and clinical outcome after nivolumab monotherapy in various subtypes of melanoma: a single-institutional retrospective study**

09:40 - 09:45
**347O - A pilot study of intrahepatic Yttrium-90 microsphere radioembolisation in combination with intravenous cisplatin for uveal melanoma liver-only metastases**
S. Arulananda¹, S. Parakh¹, M. Goodwin², M. Andrews², J. Cebon¹; ¹VIC/AU, ²ACT/AU

09:45 - 09:55
Discussion led by moderators

09:55 - 10:00
**406O - Multimodality, aggressive and sustainable care in metastatic osteosarcoma: A tertiary care cancer experience from India**
J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S. Gupta; IN

10:00 - 10:05
**407O - Clinicopathological features of wild-type GISTs based on multiple-gene panel analysis**

10:05 - 10:10
**408O - Can fairer sex, febrile neutropenia & compliance influence surviving probability in non-metastatic osteosarcoma: Experience over two decades from India**
J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S. Gupta; IN

10:10 - 10:20
Discussion led by moderators

10:15 - 11:15
**Type: Mini Oral session**
**Title: Mini Oral - Thoracic cancers**
Chair: Silvia Novello, IT; Masahiro Tsuboi, JP; Yasushi Yatabe, JP

10:15 - 10:20
**453O - Quality of life in the CHISEL randomized trial of stereotactic ablative radiotherapy (SABR) versus standard radiotherapy for stage I non-small cell lung cancer (Trans Tasman Radiation Oncology Group 09.02).**
10:20 - 10:25 466O - ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: efficacy analysis by tissue or plasma T790M test
H. Freitas1, K. Park2, D.-W. Kim2, M. Tiseo3, M. Hochmair4, G.-C. Chang5, Y.-K. Shi6, T. Moran7, Y. Chen5, J. Laskin8, B. Solomon9, M. Miranda10, J. Rigas11, P. Cheema12, S.-W. Kim2; 1SP/BR, 2KR, 3IT, 4AT, 5TW, 6CN, 7ES, 8British Columbia/CA, 9VIC/AU, 10GB, 11MD/US, 12CA

10:30 - 10:35 490O - Primary resistance mechanisms revealed in Asian TKI-sensitizing EGFR mutations NSCLC patient populations

10:35 - 10:40 491O - Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia subgroup

10:40 - 10:45 492O - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC
M.-J. Ahn1, C.-H. Chiu2, Y. Cheng3, J.-Y. Han1, S.B. Goldberg4, A. Greystoke5, J. Crawford4, Y. Zhao6, X. Huang5, M. Johnson5, K. Vishwanathan4, A. Mendoza-Naranjo5, T. Mok6; 1KR, 2TW, 3Jilin/CN, 4AL/US, 5GB, 6CN

10:45 - 10:50 493O - Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: phase 2 data

10:50 - 11:10 Discussion led by moderators
<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 11:15</td>
<td>Challenge Your Expert session</td>
<td>Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?</td>
<td>Caroline Robert, FR</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td></td>
<td>Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?</td>
<td>J. Guo, CN</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td></td>
<td>Discussion led by</td>
<td>C. Robert, FR</td>
</tr>
<tr>
<td>10:30 - 11:15</td>
<td>Challenge Your Expert session</td>
<td>Molecular biology and treatment of HCC</td>
<td>Takuji Okusaka, JP</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td></td>
<td>Molecular biology and treatment of HCC</td>
<td>L.-T. Chen, TW</td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td></td>
<td>Discussion led by</td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td>Industry Satellite Symposium</td>
<td>Industry Satellite Symposium</td>
<td></td>
</tr>
</tbody>
</table>
12:45 - 12:57 148O - Assessment of Tumor Response, Alpha-Fetoprotein (AFP) Response, and Time to Progression (TTP) in the Phase 3 CELESTIAL Trial of Cabozantinib (C) versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC)

12:57 - 13:09 152O - Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib
T. Decaens1, C. Barone2, E. Assenat1, M. Wermke3, A. Fasolo2, P. Merle1, J.-F. Blanc1, V. Grando1, R. Bruns3, J. Straub3, C. Zhao4, S. Faivre1; 1FR, 2IT, 3DE, 4MA/US

13:09 - 13:19 Invited discussant
S. Chan, HK


13:31 - 13:43 150O - Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): safety and clinical activity results from a Phase Ib study

13:43 - 13:55 151O - Practice Patterns, Radiologic Tumor Response, and Deterioration of Liver Function after Transarterial Chemoembolization (TACE): Final Analysis of OPTIMIS in Korea and Other Regions

13:55 - 14:05 Invited discussant
12:45 - 14:15  Type: Joint Symposium
Title: ESMO-AACR: ALK gene fusions: From discovery to clinical use
Chair: Tony S.K. Mok, HK

12:45 - 12:50  Introduction
T.S.K. Mok, HK

12:50 - 13:10  Talk on basic science discovery of ALK/EML4 translocation
T. Bivona, US

13:10 - 13:30  Incidence and distribution of ALK translocation in human tumours and pre-clinical evidence

13:30 - 13:50  Early-phase clinical development and identification of second and third generation of ALK inhibitors
B. Solomon, VIC/AU

13:50 - 14:10  Present indication and therapeutic strategies of ALK inhibitors in lung cancer
T.S.K. Mok, HK

14:10 - 14:15  Conclusions

12:45 - 14:15  Type: Educational session
Title: Advances in targeted therapy in gynaecological cancer
Chair: Keiichi Fujiwara, JP; Andres Maria Poveda Velasco, ES

12:45 - 13:10  Anti-angiogenic therapy in ovarian and endometrial cancer
D. Lorusso, IT

13:10 - 13:35  PARP inhibitors and synthetic lethality in ovarian cancer
E. Pujade-Lauraine, CEDEX 4/FR

13:35 - 14:00  Targeted therapy for treatment of cervical cancer
S. Gupta, IN

14:00 - 14:15  Discussion
### Multidisciplinary Tumour Board

**Title:** Locally advanced nasopharyngeal carcinoma  
**Chair:** Brigette Ma, HK; Zhang Li, CN; Melvin Lee Kiang Chua, SG; Mingyuan Chen, CN

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 12:55</td>
<td>Presentation of case/condition</td>
</tr>
<tr>
<td></td>
<td>B. Ma, HK</td>
</tr>
<tr>
<td>12:55 - 13:15</td>
<td>Timing of chemotherapy in nasopharyngeal cancer</td>
</tr>
<tr>
<td></td>
<td>Z. Li, Guangdong/CN</td>
</tr>
<tr>
<td>13:15 - 13:35</td>
<td>IMRT or proton therapy</td>
</tr>
<tr>
<td></td>
<td>M.L.K. Chua, SG</td>
</tr>
<tr>
<td></td>
<td>M. Chen, Guangdong/CN</td>
</tr>
<tr>
<td>13:55 - 14:15</td>
<td>General discussion</td>
</tr>
</tbody>
</table>

### Special Session

**Title:** Integrating BRCA testing into routine cancer care in Asia - how can it be done?  
**Chair:** Angela George, GB; Sook Yee Yoon, MY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 12:50</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>A. George, GB</td>
</tr>
<tr>
<td>12:50 - 13:10</td>
<td>Barriers to BRCA testing in Asia</td>
</tr>
<tr>
<td></td>
<td>T. Enomoto, JP</td>
</tr>
<tr>
<td>13:10 - 13:30</td>
<td>Mainstreaming cancer genetics - BRCA testing in oncology clinics</td>
</tr>
<tr>
<td></td>
<td>A. George, GB</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>Expanding BRCA testing through Malaysia - the MaGiC trial</td>
</tr>
<tr>
<td></td>
<td>S.Y. Yoon, MY</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>Overcoming distance - BRCA telephone counselling programmes</td>
</tr>
<tr>
<td></td>
<td>A. Trainer, AU</td>
</tr>
<tr>
<td>14:10 - 14:15</td>
<td>Conclusions</td>
</tr>
<tr>
<td></td>
<td>S.Y. Yoon, MY</td>
</tr>
</tbody>
</table>
### Beyond panel based mutation profiling (Hall 405)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td><strong>The maximal potential of precision medicine needs to go beyond genomic sequencing</strong>&lt;br&gt;L. Siu, Ontario/CA</td>
<td>14:30 - 14:50</td>
</tr>
<tr>
<td>14:50</td>
<td><strong>Emerging therapeutic opportunities in the non coding genome</strong>&lt;br&gt;D.S.W. Tan, SG</td>
<td>14:50 - 15:10</td>
</tr>
<tr>
<td>15:10</td>
<td><strong>Unravelling resistance to multitargeted agents based on high-throughput phosphoproteomics</strong>&lt;br&gt;M. Quintela-Fandino, ES</td>
<td>15:10 - 15:30</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Utilizing mutational signatures to inform treatment decisions</strong>&lt;br&gt;H. Davies, GB</td>
<td>15:30 - 15:50</td>
</tr>
<tr>
<td>15:50</td>
<td><strong>The evolving role of molecular tumour boards</strong></td>
<td>15:50 - 16:00</td>
</tr>
</tbody>
</table>

### Management of HER2 positive early breast cancer (Hall 404)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td><strong>Presentation of case/condition</strong>&lt;br&gt;G. Curigliano, IT</td>
<td>14:30 - 14:35</td>
</tr>
<tr>
<td>14:35</td>
<td><strong>Emerging strategies in neoadjuvant treatment of patients with HER2 early breast cancer</strong>&lt;br&gt;F. Cardoso, PT</td>
<td>14:35 - 14:55</td>
</tr>
<tr>
<td>15:15</td>
<td><strong>Optimal surgical intervention after neoadjuvant chemotherapy</strong>&lt;br&gt;W. Han, KR</td>
<td>15:15 - 15:35</td>
</tr>
<tr>
<td>15:35</td>
<td><strong>General discussion</strong></td>
<td>15:35 - 16:00</td>
</tr>
</tbody>
</table>
14:30 - 16:00  
**Type:** Special Session  
**Title:** ESMO-FACO Joint Symposium: Bridging clinical research and practice between Europe and Asia  
**Chair:** Fortunato Ciardiello, IT; Hideo Baba, JP

**Hall 407**

14:30 - 14:35  
**Introduction**  
F. Ciardiello, IT

14:35 - 14:55  
**Guidelines adaptation: Principles and achievements to date**  
G. Pentheroudakis, GR

14:55 - 15:15  
**The European-Asian contribution of practice-changing in adjuvant chemotherapy of colon cancer: The IDEA study**  
C.-H. Koehne, DE

15:15 - 15:35  
**How may clinical research on gastric cancer in Asia contribute to European management?**  
H. Baba, JP

15:35 - 15:55  
**The challenge of defining oligometastasis for breast cancer in Europe and Asia**  
Y.-H. Im, KR

15:55 - 16:00  
**Conclusions**  
H. Baba, JP

---

14:30 - 16:00  
**Type:** Educational session  
**Title:** Multidisciplinary management of retroperitoneal sarcomas  
**Chair:** Axel Le Cesne, FR; Akira Kawai, JP

**Room 324**

14:30 - 14:55  
**The role of surgery in retroperitoneal sarcomas**  
M. Fiore, IT

14:55 - 15:20  
**The role of radiotherapy in retroperitoneal sarcomas**  
R.L. Haas, NL

15:20 - 15:45  
**The role of systemic therapy in retroperitoneal sarcomas**  
H. Loong, HK

15:45 - 16:00  
**Discussion**
### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:35</td>
<td><strong>Introduction</strong></td>
<td>P.G. Casali, IT</td>
<td>Room 311</td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td><strong>What can we do on rare cancers: Lessons learned from “Rare Cancers Europe”, 10 years on</strong></td>
<td>P.G. Casali, IT</td>
<td>Room 311</td>
</tr>
<tr>
<td>14:50 - 15:05</td>
<td><strong>Incidence of rare cancers: Results of an epidemiological comparison effort between Asia and Europe</strong></td>
<td>A. Trama, IT</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:05 - 15:20</td>
<td><strong>Which cancers are really rare in Asia?</strong></td>
<td>Y.-J. Won, KR</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:20 - 15:35</td>
<td><strong>The epidemiological/biological enigma of nasopharyngeal carcinoma from a European perspective</strong></td>
<td>L. Licitra, IT</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:35 - 15:50</td>
<td><strong>How to address the research questions on nasopharyngeal carcinoma: The case for an Asian/European partnership</strong></td>
<td>A. Chan, HK</td>
<td>Room 311</td>
</tr>
<tr>
<td>15:50 - 16:05</td>
<td><strong>A clinical-pathologic web Sarcoma Tumor Board between Asia and Europe</strong></td>
<td>A.P. Dei Tos, IT</td>
<td>Room 311</td>
</tr>
<tr>
<td>16:05 - 16:20</td>
<td><strong>Discussion</strong></td>
<td></td>
<td>Room 311</td>
</tr>
<tr>
<td>16:20 - 16:30</td>
<td><strong>Conclusions: Towards “Rare Cancers Asia”</strong></td>
<td>R. Quek, SG</td>
<td>Room 311</td>
</tr>
</tbody>
</table>